<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2681241-A1" country="EP" doc-number="2681241" kind="A1" date="20140108" family-id="44262467" file-reference-id="252638" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587025" ucid="EP-2681241-A1"><document-id><country>EP</country><doc-number>2681241</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12710343-A" is-representative="NO"><document-id mxw-id="PAPP154849217" load-source="docdb" format="epo"><country>EP</country><doc-number>12710343</doc-number><kind>A</kind><date>20120228</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220440249" load-source="docdb" format="original"><country>EP</country><doc-number>12710343.0</doc-number><date>20120228</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140547773" ucid="EP-11156131-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>11156131</doc-number><kind>A</kind><date>20110228</date></document-id></priority-claim><priority-claim mxw-id="PPC140554445" ucid="EP-12710343-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>12710343</doc-number><kind>A</kind><date>20120228</date></document-id></priority-claim><priority-claim mxw-id="PPC140555166" ucid="IB-2012050909-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>IB</country><doc-number>2012050909</doc-number><kind>W</kind><date>20120228</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989316731" load-source="docdb">C07K  16/12        20060101AFI20120920BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989321815" load-source="docdb">G01N  33/569       20060101ALI20120920BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989635019" load-source="docdb" scheme="CPC">A61K2039/507       20130101 LA20131203BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989641386" load-source="docdb" scheme="CPC">G01N2800/709       20130101 LA20131203BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989648693" load-source="docdb" scheme="CPC">G01N2333/31        20130101 LA20131203BHEP        </classification-cpc><classification-cpc mxw-id="PCL2007296122" load-source="docdb" scheme="CPC">C07K  16/1271      20130101 LI20140207BHEP        </classification-cpc><classification-cpc mxw-id="PCL2007296123" load-source="docdb" scheme="CPC">G01N  33/56938     20130101 FI20140207BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365708" lang="DE" load-source="patent-office">VERARMTE POLYKLONALE ANTI-STAPHYLOKOKKEN-ENTEROTOXIN-ANTIKÖRPER, HERSTELLUNG UND VERWENDUNGEN DAVON</invention-title><invention-title mxw-id="PT132365709" lang="EN" load-source="patent-office">DEPLETED ANTI-STAPHYLOCOCCAL ENTEROTOXINS POLYCLONAL ANTIBODIES, PREPARATION AND USES THEREOF</invention-title><invention-title mxw-id="PT132365710" lang="FR" load-source="patent-office">ANTICORPS POLYCLONAUX APPAUVRIS ANTI-ENTÉROTOXINES STAPHYLOCOCCIQUES, PRÉPARATION ET UTILISATIONS ASSOCIÉES</invention-title><citations><non-patent-citations><nplcit><text>See references of WO 2012117342A1</text><sources><source mxw-id="PNPL67456268" load-source="docdb" name="SEA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919504970" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV STRASBOURG</last-name><address><country>FR</country></address></addressbook></applicant><applicant mxw-id="PPAR919537048" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>UNIVERSITE DE STRASBOURG</last-name></addressbook></applicant><applicant mxw-id="PPAR919010495" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Université de Strasbourg</last-name><iid>101277929</iid><address><street>4, rue Blaise Pascal</street><city>67000 Strasbourg</city><country>FR</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919514309" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PREVOST GILLES</last-name><address><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919506188" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>PREVOST, GILLES</last-name></addressbook></inventor><inventor mxw-id="PPAR919008930" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>PRÉVOST, Gilles</last-name><address><street>8 rue Socrate</street><city>67170 Brumath</city><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919522742" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>BARASINO CHARLINE</last-name><address><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919541774" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>Barasino, Charline</last-name></addressbook></inventor><inventor mxw-id="PPAR919009936" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Barasino, Charline</last-name><address><street>4 rue de la Verdure</street><city>68200 Mulhouse</city><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919534627" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>KELLER DANIEL</last-name><address><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919545771" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>KELLER, DANIEL</last-name></addressbook></inventor><inventor mxw-id="PPAR919007326" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>KELLER, DANIEL</last-name><address><street>12 rue de la Coudreuse</street><city>67200 Strasbourg</city><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919534663" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>MASOUD KHALDOUN</last-name><address><country>SY</country></address></addressbook></inventor><inventor mxw-id="PPAR919515108" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>MASOUD, Khaldoun</last-name></addressbook></inventor><inventor mxw-id="PPAR919019670" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>MASOUD, Khaldoun</last-name><address><street>P.O. Box 680 Afamia</street><city>Latakia</city><country>SY</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919012736" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Novagraaf Technologies</last-name><iid>101103525</iid><address><street>122, rue Edouard Vaillant</street><city>92593 Levallois-Perret Cedex</city><country>FR</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="IB-2012050909-W"><document-id><country>IB</country><doc-number>2012050909</doc-number><kind>W</kind><date>20120228</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012117342-A1"><document-id><country>WO</country><doc-number>2012117342</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549767885" load-source="docdb">AL</country><country mxw-id="DS549849911" load-source="docdb">AT</country><country mxw-id="DS549767590" load-source="docdb">BE</country><country mxw-id="DS549780334" load-source="docdb">BG</country><country mxw-id="DS549917678" load-source="docdb">CH</country><country mxw-id="DS549767591" load-source="docdb">CY</country><country mxw-id="DS549848663" load-source="docdb">CZ</country><country mxw-id="DS549767886" load-source="docdb">DE</country><country mxw-id="DS549767592" load-source="docdb">DK</country><country mxw-id="DS549767597" load-source="docdb">EE</country><country mxw-id="DS549849948" load-source="docdb">ES</country><country mxw-id="DS549780335" load-source="docdb">FI</country><country mxw-id="DS549780336" load-source="docdb">FR</country><country mxw-id="DS549767887" load-source="docdb">GB</country><country mxw-id="DS549767598" load-source="docdb">GR</country><country mxw-id="DS549767888" load-source="docdb">HR</country><country mxw-id="DS549848664" load-source="docdb">HU</country><country mxw-id="DS549917679" load-source="docdb">IE</country><country mxw-id="DS549767599" load-source="docdb">IS</country><country mxw-id="DS549780349" load-source="docdb">IT</country><country mxw-id="DS549767600" load-source="docdb">LI</country><country mxw-id="DS549780350" load-source="docdb">LT</country><country mxw-id="DS549849912" load-source="docdb">LU</country><country mxw-id="DS549780351" load-source="docdb">LV</country><country mxw-id="DS549780352" load-source="docdb">MC</country><country mxw-id="DS549849913" load-source="docdb">MK</country><country mxw-id="DS549849918" load-source="docdb">MT</country><country mxw-id="DS549849949" load-source="docdb">NL</country><country mxw-id="DS549864307" load-source="docdb">NO</country><country mxw-id="DS549849954" load-source="docdb">PL</country><country mxw-id="DS549780365" load-source="docdb">PT</country><country mxw-id="DS549848665" load-source="docdb">RO</country><country mxw-id="DS549780366" load-source="docdb">RS</country><country mxw-id="DS549849955" load-source="docdb">SE</country><country mxw-id="DS549917680" load-source="docdb">SI</country><country mxw-id="DS549864308" load-source="docdb">SK</country><country mxw-id="DS549864309" load-source="docdb">SM</country><country mxw-id="DS549849919" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99835314" ref-ucid="WO-2012117342-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to the preparation of a set of depleted polyclonal antibodies,each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and its use for multiplex detection.</p></abstract><abstract mxw-id="PA100331148" ref-ucid="WO-2012117342-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to the preparation of a set of depleted polyclonal antibodies,each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and its use for multiplex detection.</p></abstract><abstract mxw-id="PA99835315" ref-ucid="WO-2012117342-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne la préparation d'un ensemble d'anticorps polyclonaux appauvris, chaque anticorps polyclonal appauvri étant dirigé contre une entérotoxine staphylococcique spécifique, et son utilisation pour la détection multiplex.</p></abstract><abstract mxw-id="PA100331149" ref-ucid="WO-2012117342-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne la préparation d'un ensemble d'anticorps polyclonaux appauvris, chaque anticorps polyclonal appauvri étant dirigé contre une entérotoxine staphylococcique spécifique, et son utilisation pour la détection multiplex.</p></abstract><description mxw-id="PDES51232952" ref-ucid="WO-2012117342-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> DEPLETED ANTI-STAPHYLOCOCCAL ENTEROTOXINS POLYCLONAL ANTIBODIES, PREPARATION AND USES THEREOF </p><p id="p0002" num="0002">DESCRIPTION </p><p id="p0003" num="0003">Technical domain </p><p id="p0004" num="0004"> The present invention relates to the multiplex titration of staphylococcal enterotoxins allowing simultaneous specific and quantitative detections with lower limits and with a higher magnitude of response. To this aim, the present invention uses affinity-purified and step-by-step immunoabsorbed or depleted polyclonal antibodies raised against staphylococcal enterotoxins. </p><p id="p0005" num="0005"> The present invention finds an application in dairy products but also in human clinics, veterinary clinics, drugs control, meat and egg products. </p><p id="p0006" num="0006"> In the specification below, references in square brackets ([ ]) refer to the list of references presented at the end of the text. </p><p id="p0007" num="0007">State of the art </p><p id="p0008" num="0008"> An enterotoxin is a protein toxin released by a microorganism in the intestine. Enterotoxins are chromosomally encoded exotoxins that are produced and secreted from several bacterial organisms, for example Escherichia coli 0157.H7, Clostridium perfringens, Vibrio cholerae, Staphylococcus aureus (also known as golden cluster seed, seed gold, or golden staph), Yersinia enterocolitica, Shigella dysenteriae. They are often heat-stable, and are of low molecular weight and water-soluble. Enterotoxins are frequently cytotoxic and kill cells by altering the apical membrane permeability of the mucosal (epithelial) cells of the intestinal wall. They are mostly pore-forming toxins (mostly chloride pores), secreted by bacteria, that assemble to form pores in cell membranes. This causes the cells to die. </p><p id="p0009" num="0009"> Staphylococcal enterotoxins (SEs) are basic proteins highly toxic produced by certain Staphylococcus strains in a variety of environments, including food substrates. SEs are exoproteins with a molecular weight between 22 and 29kDa showing neurotoxic properties in humans. In addition, SEs are powerful superantigens that stimulate non-specific T-cell proliferation, and share close phylogenetic relationships, with similar structures and activities. To date, 23 different SEs have been identified. Types of toxins SEA, SEB, SEC, SED and SEE represent "conventional" toxins because well-characterized and identified for many years, and which involvement in cases of food poisoning has been shown by many authors [Jones and Kahn, J. Bacterid., 166 : 29-33, 1986; Betley and Mekalanos, J. Bacterid., 170(1 ) : 34-41 , 1988; Couch and al., J. Bacterid., 
<!-- EPO <DP n="3"/>-->
 170 : 2954-2960, 1988; Bayles and landolo, J. Bacterid., 171 : 4799-4806, 1989; Dingues and al., Clin. Microbiol. Rev., 13 : 16-34, 2000] [1 -5]. Serotype C was subdivided in groups (SEC1 , SEC2, SEC3, SEC<sub>b0</sub>vine, SEC<sub>0V</sub>ine, SEC<sub>goa</sub>t and SECca<sub>n</sub>i<sub>n</sub>e) classified according to differences of superantigen activity and depending on the host to which they are associated [Bergdoll and al., J. Bacterid., 90(5) : 1481 -1485, 1965; Marr and al., Infect. Immun., 61 : 4254-4262, 1993] [6, 7]. A staphylococcal enterotoxin SEF was described in 1981 [Bergdoll, Lancet, 1 : 1017-1021 , 1981] [8], but was renamed a few years later TSST1 given its lack of emetic activity unlike other conventional enterotoxins [Blomster- Hautamaa and al., J. Biol. Chem., 261 : 15783-15786, 1986] [9]. Since the mid- 1990s, from the genome analysis of S. aureus, several genes with strong sequence homology with genes of conventional enterotoxins have been identified. These genes encode proteins with structural properties similar to those of enterotoxins whose emetic activity has rarely been demonstrated. In 2004, a new nomenclature for the superantigens expressed by S. aureus has been proposed for the designation of these new enterotoxins [Lina and al., J. Infect. Dis., 189(12) : 2334-2336, 2004] [10]. Accordingly, only the toxins inducing emetic activity after oral administration in animals have been designated staphylococcal enterotoxins (SEs), namely types of toxins SEA, SEB, SEC, SED, SEE, SEG, SEH and SEI. Other toxins, for which no emetic activity has been demonstrated in vivo, have been called "staphylococcal enterotoxin-like" to indicate that their role in food poisoning was not confirmed [Ren et al., J. Exp. Med., 180(5) : 1675-1683, 1994; Jarraud and al., J. Immunol., 166(1 ) : 669-677, 2001 ; Orwin and al., Infect. Immun., 69(1 ) : 360-366, 2001 ; Letertre and al., Mol. Cell Probes, 17 : 227-235, 2003; Omoe and al., J. Clin. Microbiol., 40 : 857-862, 2002; Su and Wong, J. Food Prot., 59(3) : 327-330, 1996; Munson and al., Infect. Immun., 66 : 3337-3348, 1998] [1 1 -17]. In 2008, two new enterotoxins SES and SET were cloned and purified which show an emetic activity in animals, as newly confirmed for the enterotoxin SER [Ono and al., Infect. Immun., 76(1 1 ) : 4999-5005, 2008] [18]. </p><p id="p0010" num="0010"> The most sensitive methods to detect toxins are the polymerase chain reaction (PCR) and enzyme-linked immunoabsorbent assay (ELISA). The PCR- related methods are more suitable for detection of organisms, such as bacteria and viruses, from which nucleic acids can be extracted for specific amplification. The ELISA-based methods are more robust for detection of toxins, which are often proteins in nature, using specific polyclonal or monoclonal antibodies when available. In comparison with the PCR method, the ELISA-based detection is less sensitive to the matrix effect and presumably gives fewer false-positive 
<!-- EPO <DP n="4"/>-->
 results, and ELISA can be addressed to thermostable proteins while bacteria may disappear in slightly heated foods. </p><p id="p0011" num="0011"> All the staphylococcal toxins share similarities in amino acid sequence homology ranging from 15,5% (between SEB and SEK) to 81 % (between SEA and SEE) which can lead to lack of specificity of tools used for their detection. Moreover up to date, the titration of staphylococcal enterotoxins is achieved antigen by antigen (which is extremely time consuming) and it is proposed to a limited number (4 or 5) of staphylococcal enterotoxins involved in food-born intoxination issued from dairy products. Commercial kits are qualitative but when quantitative, they generally lack specificity (which does not allow to easily conduct epidemiological links) and/or sensitivity (which puts the tests over the limits of human toxicity threshold of staphylococcal enterotoxins). Furthermore no commercial kit has been able to fulfil national and international standards (e.g. AFNOR in France). </p><p id="p0012" num="0012"> Therefore, there is a real need to identify new methods for detection and specific titration of staphylococcal enterotoxins, that overcomes the shortcomings, disadvantages and obstacles of prior art, and thereby improving the management of staphylococcal enterotoxins contaminations, notably those induced by enterotoxins from Staphylococcus aureus, while reducing costs and time consumption. </p><p id="p0013" num="0013">Description of the invention </p><p id="p0014" num="0014"> The Inventors have now developed unexpectedly a multiplex assay that allows simultaneously the specific titration of at least staphylococcal enterotoxins A, B, C, D, E, G, H and I. Any of the cited antigens are expressed in a recombinant form that remains functional and does not harbour significant difference in their epitopes. These antigens are used for immunizations, and serve as controls in the test assays. The titration was based on the Luminex<sup>®</sup> technology and uses rabbit polyclonal antibodies that were affinity-purified, and secondarily step-by-step immunoabsorbed or depleted against cross-reacting enterotoxins to reach a strict specificity which preserves affinity and sensitivity of a bulk of specific polyclonal antibodies only for the corresponding antigen. The multiplex titration finally allows simultaneous specific and quantitative detections with lower limits close to 50-80pg/g of initial products, e.g. culture supernatants, dairy products, human serum and with at least a more than two logarithmic magnitude of response. Such a simultaneous titration offers homogeneity and possibilities to detect toxin concentrations that would remain below the human toxicity threshold. Such a simultaneous titration conjoined to a low consummation 
<!-- EPO <DP n="5"/>-->
 of the developed products brings decreased cost compared to those actually observed for these assays and reduces time for results. </p><p id="p0015" num="0015"> The present invention, therefore, relates to an immunological composition comprising a mixture of at least two depleted polyclonal antibodies each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and a pharmaceutically acceptable carrier. Preferably, it relates to an immunological composition comprising a mixture of at least three, four, five, six, seven or eight depleted polyclonal antibodies each depleted polyclonal antibody being raised or directed against one specific staphylococcal enterotoxin, and a pharmaceutically acceptable carrier. According to the present invention, it may be in particular depleted polyclonal antibodies each polyclonal antibody being raised against one specific staphylococcal enterotoxin chosen from the group consisting of the staphylococcal enterotoxins A, B, C, D, E, G, H, and I. </p><p id="p0016" num="0016"> "Depleted polyclonal antibodies" within the meaning of the present invention means a set of polyclonal antibodies, each polyclonal antibody being raised and/or directed against a given staphylococcal enterotoxin (immunogen), different from each other, that is affinity-purified and secondarily step-by-step immunoabsorbed (or depleted) against cross-reacting enterotoxin(s) that are different from the staphylococcal enterotoxin used as immunogen, to reach a strict specificity which preserves affinity and sensitivity of a bulk of specific polyclonal antibodies only for the corresponding given staphylococcal enterotoxin (immunogen). Said step-by-step immunoabsorbed or depleted polyclonal antibodies are not conjugated to a support as conventional immunoabsorbed antibodies at the end of steps of purification and step-by-step immunoabsorbtion / depletion, but can be subsequently linked to a support if necessary. </p><p id="p0017" num="0017"> "Pharmaceutically acceptable carrier" within the meaning of the present invention means any and all solvents, disintegrating agents, binders, excipients, lubricants, absorption delaying agents and the like. </p><p id="p0018" num="0018"> "Staphylococcal enterotoxins A, B, C, D,E, G, H and I" within the meaning of the present invention means the staphylococcal enterotoxins (SEs), namely types of toxins SEA, SEB, SEC, SED, SEE, SEG, SEH and SEI, produced by Staphylococcus aureus. </p><p id="p0019" num="0019"> The present invention also relates to a method for multiplex detection of staphylococcal enterotoxins, comprising: </p><p id="p0020" num="0020"> a) contacting a sample with an immunological composition of the invention ; b) detecting potential immunological complexes formed. </p><p id="p0021" num="0021"> "A sample" within the meaning of the present invention means any culture media, biological samples (e.g. human clinical samples) or food extracts that are susceptible of being contaminated by staphylococcal enterotoxins. For example, 
<!-- EPO <DP n="6"/>-->
 it includes culture supernatants, human serum, dairy/egg/meat/prepared meals/sea foods products /spices/drugs and surface of medical devices, and any extracts or protein preparation issued from the cited stuffs. </p><p id="p0022" num="0022"> "Immunological complexes" within the meaning of the present invention means the complexes formed between the depleted polyclonal antibody and its immunogen (namely the given staphylococcal enterotoxin used for immunization). </p><p id="p0023" num="0023"> The detection of said immunological complexes can be performed by any means known in the art. For example, it includes protein mass - based technologies {e.g. protein CHIPS assisted by SELDI-TOF or MALDI-TOF, fluorescence-based technologies (e.g. Luminex technology), surface plasmon resonnance-based technologies (biosensors). </p><p id="p0024" num="0024"> According to a particular embodiment of the present invention, said method for multiplex detection can also include a step c) wherein the detection results obtained in step b) are compared to a negative and / or positive control. </p><p id="p0025" num="0025"> "Positive and / or negative control" within the meaning of the present invention means a control sample comprising or not at least one staphylococcal enterotoxin, respectively. This control allows to compare the detection results obtained in step b) of the method of the invention and to detect a false positive or false negative, if any. </p><p id="p0026" num="0026"> According to a particular embodiment of the present invention, said method of multiplex detection can also include a step Cbis) wherein the detection results obtained in step b) are compared to a standard of measurement; allowing a qualitative and / or quantitative analysis of staphylococcal enterotoxins. </p><p id="p0027" num="0027"> "Standard of measurement" within the meaning of the present invention means one or more analysis carried out on solutions manufactured for analytical purposes according to the invention and comprising a known staphylococcal enterotoxin(s) content. From the analysis results, it is thus possible to determine the presence of staphylococcal enterotoxin(s) in the sample as well as its concentration by comparison, for example using a standard curve made from standards or measurement. </p><p id="p0028" num="0028"> According to the present invention, steps c) and Cbis) can be both implemented, before or after steps a) and b) of the method of the invention. According to the present invention, steps c) and Cbis) can be implemented simultaneously or sequentially, including to steps a) and b), for example on a multi-well plate for performing several analysis simultaneously or sequentially, including measures of standards. 
<!-- EPO <DP n="7"/>-->
 The present invention also relates to the use of an immunological composition of the invention, as a diagnostic tool of a staphylococcal enterotoxin(s) contamination. </p><p id="p0029" num="0029"> Such a diagnostic tool allows a qualitative and/or quantitative diagnosis of a staphylococcal enterotoxin(s) contamination. </p><p id="p0030" num="0030"> The present invention also relates to a kit for the multiplex detection of staphylococcal enterotoxins, comprising an immunological composition of the invention and means for the detection of immunological complexes. </p><p id="p0031" num="0031"> "Means for the detection of immunological complexes" within the meaning of the present invention means any means well known in the art. For example, it includes Cy5, phycoerythrin or any other fluorescent dyes, fluorescent metabolites issued from enzymes activity, Matrix assisted laser desorption ionization procedures, Fluorescent resonance energy transfer, surface plasmon resonance. </p><p id="p0032" num="0032"> The present invention also relates to a method for the preparation of a depleted polyclonal antibody raised and/or directed against one specific staphylococcal enterotoxin, comprising: </p><p id="p0033" num="0033"> a) providing an anti-enterotoxin polyclonal antibody previously obtained from the immunization of a non-human animal with a given staphylococcal enterotoxin ; </p><p id="p0034" num="0034"> b) purification of said anti-enterotoxin polyclonal antibody using at least two successive immunoabsorption (or depletion) steps against immunization- unrelated staphylococcal enterotoxins and which order is chosen to abolish cross-reactions with said immunization-unrelated staphylococcal enterotoxins from the strongest cross-reaction to the weaker cross-reaction. </p><p id="p0035" num="0035"> "Immunization-unrelated staphylococcal enterotoxins" within the meaning of the present invention means given staphylococcal enterotoxin(s) Y (SEY) that differ(s) from a given staphylococcal enterotoxin X (SEX), used as immunogen for obtaining a polyclonal antibody raised against said given staphylococcal enterotoxin X (SEX), but that is responsible for a cross reaction with said anti- SEX polyclonal antibody. </p><p id="p0036" num="0036"> For example, step b) is carried out by purification / depletion of an affinity purified anti-SE polyclonal antibody on an immunoabsorption column with a first immunization-unrelated staphylococcal enterotoxin immobilized thereon responsible for a cross reaction. If a cross reaction remains, a new purification / depletion is carried out on an immunoabsorption column with the same or another immunization-unrelated staphylococcal enterotoxin responsible for the cross reaction. These purification steps are repeated until obtaining monospecificity of depleted polyclonal antibody with respect to its immunogen. 
<!-- EPO <DP n="8"/>-->
 The order of successive columns can be easily determined by one skilled in the art according to the extent of each cross reaction detected, namely from the stronger cross reactivity to the weaker cross-reactivity. Preferably, said method for the preparation of a depleted anti-SE polyclonal antibody can also include washing steps between each purification step. </p><p id="p0037" num="0037"> According to a particular embodiment of the present invention, said method for the preparation of a depleted anti-SE polyclonal antibody can also include a step c) wherein the specificity of said depleted polyclonal antibody is monitored by any means well known in the art. For example, the specificity of the depleted anti-SE polyclonal antibody can be controlled by ELISA, DOT-BLOT against its immunogen and/or one or more parent staphylococcal enterotoxin(s) to detect the presence of remaining cross reaction, if any. Preferably, one or more analysis is(are) carried out on solutions manufactured for analytical purposes according to the invention and comprising the known immunogen or an immunization- unrelated staphylococcal enterotoxin content. From the analysis results, it is thus possible to determine the presence of any cross reaction as well as its extent by comparison, for example using a standard curve made from standards of measurement. </p><p id="p0038" num="0038"> According to the present invention, step c) can be implemented between each depletion step and/or at the end of step b). Preferably step c) is implemented between each depletion step to detect remaining cross reaction(s), determine the extent of each cross reaction detected, and thus determine the necessary next depletion step(s) to achieve monospecificity. </p><p id="p0039" num="0039"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SEA comprises a step b) wherein 5 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin E, E, I, B, then D are implemented. </p><p id="p0040" num="0040"> According to a particular embodiment of the present invention, the method for the preparation of an immunoabsorbed polyclonal antibody against SEB comprises a step b) wherein 3 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin C1 , C1 , then G are implemented. </p><p id="p0041" num="0041"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SEC comprises a step b) wherein 3 successive depletion steps against immunization-unrelated staphylococcal enterotoxin B, B, then G are performed. </p><p id="p0042" num="0042"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SED comprises a 
<!-- EPO <DP n="9"/>-->
 step b) wherein 3 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin A, A, then E are performed. </p><p id="p0043" num="0043"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SEE comprises a step b) wherein 4 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin A, A, I, then C1 are performed. </p><p id="p0044" num="0044"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SEG comprises a step b) wherein 4 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin A, B, I, then C1 are performed. </p><p id="p0045" num="0045"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SEH comprises a step b) wherein 2 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin B, then D. </p><p id="p0046" num="0046"> According to a particular embodiment of the present invention, the method for the preparation of a depleted polyclonal antibody against SEI comprises a step b) wherein 5 successive depletion steps against immunization-unrelated staphylococcal enterotoxin E, C1 , G, B, then A are performed. </p><p id="p0047" num="0047"> The present invention also relates to a depleted anti-SE polyclonal antibody raised against a staphylococcal enterotoxin obtained by a method for the preparation of a depleted anti-enterotoxin polyclonal antibody of the invention. Such depleted anti-enterotoxin polyclonal antibodies differ from those of the art by a different population of antibodies, affinity and specificity to the corresponding antigen. </p><p id="p0048" num="0048"> For example depleted anti-SE polyclonal antibodies of the invention are available free in solutions or adsorbed on a support, for example a bead (microsphere or nanoparticle), but can be adsorbed also onto a protein microarray, a functionalized multiwell plate, etc.... Preferably, such depleted polyclonal antibodies are adsorbed on beads, more preferably on beads of an unique color-code according to the strict specificity of the depleted anti-SE polyclonal antibody of the invention adsorbed thereon. </p><p id="p0049" num="0049">Brief description of the figures </p><p id="p0050" num="0050"> - Figure 1 represents the pGEX-6P-1 expression vector containing a resistance gene to ampicillin and two restriction sites for BamH1 (loc.945) and EcoR1 (loc. 954). </p><p id="p0051" num="0051"> - Figure 2 represents the amino acids sequences of staphylococcal enterotoxinsSEA-l. 
<!-- EPO <DP n="10"/>-->
 - Figure 3 represents the synthesis of the calibration curves for plates 100 to 104. </p><p id="p0052" num="0052"> - Figure 4 represents the titration curves of staphylococcal enterotoxins SEA-I. </p><p id="p0053" num="0053">- Figure 5 represents the LOD and LOQ for plates 100 to 104 +/- standard deviation. </p><p id="p0054" num="0054"> - Figure 6 represents the linearity of standard for plates 100 to104. </p><p id="p0055" num="0055"> - Figure 7 represents SEs titration on Munster after caseins precipitation and delipidation </p><p id="p0056" num="0056">- Figure 8 represents SEs titration on concentrated matrix after caseins precipitation and delipidation. 
<!-- EPO <DP n="11"/>-->
</p><p id="p0057" num="0057">EXAMPLES </p><p id="p0058" num="0058">EXAMPLE 1 : ORIGINS OF THE 8 STAPHYLOCOCCAL ENTEROTOXINS Sources of the basic Staphylococcus aureus strains used for cloning </p><p id="p0059" num="0059"> The genes fragments corresponding to the 8 Staphylococcal enterotoxins (SEs) secreted sequences were obtained from strict amplification (Phusion™ High Fidelity DNA Polymerase) of genes from strains listed in the table 1 below. </p><p id="p0060" num="0060"> Table 1 </p><p id="p0061" num="0061"><img id="imgf000011_0001" he="92" wi="133" file="imgf000011_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0062" num="0062">Cloned genes have been checked by nucleotide sequencing. Oligonucleotides adjustable to the plasmid pGEX-6P-1 were used for an insertion either in the EcoR1 cut site (protein + 8 amino acids), or in the BamW cut site (protein +5 amino acids). Antigens are over-expressed from recombinant clones pGEX-6P-1 (SEA+5, SEB+5, SEC1 +8, SEE+5, SEG+8, SEH+5 and SEI+5) transforming BL21 as Glutathion S-Transferase (GST) fusion proteins, then purified by glutathion affinity (Sepharose4B GSH) followed by a cation exchange chromatography (Mono S), adapted to each SE. All SEs have purity over 90-95% in SDS-PAGE. SEA+5, SEB+5, SEC1 +8 are recognized by the kit Oxoid SET RPLA and SEE+5 by Oxoid anti-SEA from the same kit. </p><p id="p0063" num="0063">Bacterial strains </p><p id="p0064" num="0064"> Escherichia, coli XL1 -Blue </p><p id="p0065" num="0065">Genotype : recA1 endA1 gyrA96 thi-1 hsdRU supE44 relA1 lac [F<sup>'</sup> proAB /ac^ZAM? 5 Tn 70 (Tet<sup>r</sup>)] </p><p id="p0066" num="0066"> Escherichia coli BL21 
<!-- EPO <DP n="12"/>-->
 Genotype : E. coli B F- dcm ompT hsdS (r<sub>B</sub>- m<sub>B</sub>-) gal </p><p id="p0067" num="0067">Plasmid Vector (pGEX-6P-1) </p><p id="p0068" num="0068"> It is a 4984 pb vector (figure 1 ) containing an ampicillin resistance gene, a gene coding to the Glutathion-S-Transferase (GST) and a multiple cloning region located in 3' of that gene. </p><p id="p0069" num="0069"> Cloned sequences in multiple restriction/insertion sites of pGEX-6P-1 vector can be expressed as GST fusion proteins located at its N-terminal extremity [Smith and Johnson, Gene, 67(1 ) : 31 -40, 1988] [19]. Expression is under the control of the ptac promoter, upstream the GST coding gene, which is induced by the isopropyl β-D thiogalactopyranoside (IPTG). The fusion protein expressed in the pGEX-6P-1™ can easily be purified by affinity chromatography using a Glutathion Sepharose 4B™ column (GE Healthcare, Orsay). The fusion protein contains a specific proteolysis site using PreScission™ Protease (GE Healthcare, Orsay), and is located between the GST and its fusion partner. </p><p id="p0070" num="0070">Recombined vectors </p><p id="p0071" num="0071"> Recombined vectors used are made in the first part of work by the cloning method (table 2). </p><p id="p0072" num="0072"> Table 2 </p><p id="p0073" num="0073"><img id="imgf000012_0001" he="67" wi="108" file="imgf000012_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0074" num="0074">DNA primers used for genetic amplification (PCR) </p><p id="p0075" num="0075"> Oligonucleotides used for the genetic amplification of the genes coding the staphylococcal enterotoxins are shown in the table 3 below. 
<!-- EPO <DP n="13"/>-->
 Table 3 </p><p id="p0076" num="0076"><img id="imgf000013_0001" he="227" wi="156" file="imgf000013_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><!-- EPO <DP n="14"/>-->
 Table 3 (suite et fin) </p><p id="p0077" num="0077"><img id="imgf000014_0001" he="72" wi="156" file="imgf000014_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0078" num="0078">Media </p><p id="p0079" num="0079"> - 2 x TY (Trypcase-Yeast extract) medium: 1 .6% (p/v) bio-trypcase (BioMerieux), 1 % (p/v) yeast extract (Bio-Rad), 0.5% (p/v) NaCI pH 7.4. The agar medium contains 1 .5% (p/v). </p><p id="p0080" num="0080"> - 2 x TYA medium: 2 x TY medium containing 10O g/mL of ampicilline.</p><p id="p0081" num="0081">- M9 medium : 15 g/L Na<sub>2</sub>HPO<sub>4</sub>-12H<sub>2</sub>O, 3 g/L KH<sub>2</sub>PO<sub>4</sub>, 1 g/L NH<sub>4</sub>CI, 0.5 g/L NaCI, 15 g/L agar. Following the autoclave add : 1 ml_ 0.1 M CaCI<sub>2</sub>, 1 mL 1 M MgSO<sub>4</sub>, 1 mL 1 M Thiamine-HCI, 2mL 20% (p/v) Glucose </p><p id="p0082" num="0082"> - Strains freezing medium: 90% (v/v) Brain Heart Infusion (Difco), 10% (v/v) glycerol (87%). </p><p id="p0083" num="0083">Reagents and buffers </p><p id="p0084" num="0084"> TEB 10 X : 0.89 M Tris-base, 0,89 M boric acid, 25 mM EDTA-Na<sub>2</sub> (Titriplex III), pH 8.3. </p><p id="p0085" num="0085"> TE: 10 mM Tris-HCI, 1 mM EDTA-Na2, pH 8.0. </p><p id="p0086" num="0086"> TEG : 25 mM Tris-HCI, 50 mM Glucose, 10 mM EDTA ; pH 8.0. </p><p id="p0087" num="0087">Alkaline Lysis Buffer(ALB): 0.2 M NaOH, 1 % (m/v) SDS. </p><p id="p0088" num="0088">Plasmid DNA preparation reagents (Plasmid-combi-kit, Qiagen) : </p><p id="p0089" num="0089"> - Buffer P1 : 50 mM Tris-HCI, 10 mM EDTA-Na<sub>2</sub> pH 8.0 ; 100 Mg/mL RNase A.</p><p id="p0090" num="0090">- Buffer P2: 200 mM NaOH, 1 % (m/v) SDS. </p><p id="p0091" num="0091"> - Buffer P3: 3.0 M Potassium acetate, pH 5.5. 
<!-- EPO <DP n="15"/>-->
 - Buffer QC: 50 mM MOPS, 1 M NaCI, pH 7.0, 15% (v/v) ethanol. </p><p id="p0092" num="0092"> - Buffer QBT: 50 mM MOPS, 750 mM NaCI, pH 7.0, 15% (v/v) ethanol, 0.15% (v/v) Triton X100. </p><p id="p0093" num="0093"> - Buffer QF: 50 mM Tris-HCI, 1 ,25 M NaCI, pH 8.5, 15% (v/v) ethanol. x 5 DNA denaturating solution: 25 mM EDTA-Na<sub>2</sub> pH 8.0, 20% (m/v) glycerol, 0.5% (m/v) lauroyi sarcosine, 0.1 % (m/v) Bromophenol blue. This solution leads to DNA denaturation and can be used as a migration control in agarose gel electrophoresis. </p><p id="p0094" num="0094">- SDS-PAGE loading buffer: 0.2 M Tricine, 0.2 M Tris-base, 0.55% (m/v) SDS, pH 8.0. </p><p id="p0095" num="0095"> - Coomassie blue coloration stock solution: 0.2 g Coomassie blue G250 R (GE Healthcare), 60% (v/v) methanol, QSP 200 ml_ with H<sub>2</sub>O. </p><p id="p0096" num="0096"> - Coomassie Blue coloration finale solution: 50 % (v/v) of filtered stock solution, 10% (v/v) acetic acid, 30 % (v/v) methanol. </p><p id="p0097" num="0097"> - PBS: 2.7 mM KCI, 10 mM, Na<sub>2</sub>HPO<sub>4</sub>, 1 .8 mM KH<sub>2</sub>PO<sub>4</sub>, 140 mM NaCI, pH 7.4.</p><p id="p0098" num="0098">- Lysis Buffer A: 20 mM HEPES, NaCI 150 mM, EDTA 1 mM pH 7.2. </p><p id="p0099" num="0099">Buffer B: 100 mM Acetic acid, 500 mM NaCI, pH 4.0. </p><p id="p0100" num="0100"> - Elution buffer C: 50mM Tris-hydroxyamino methyl-HCI, 500 mM, NaCI, 30 mM GSH, pH 8.0. </p><p id="p0101" num="0101">Preparation of Staphylococcus aureus total DNA </p><p id="p0102" num="0102"> From a 5 ml_ preculture of the corresponding strain of S. aureus, inoculate 2x 10 ml_ of 2x TY medium at 37°C overnight. Spin 10 min at 5000 xg. Wash the pellet with water. Resuspend in 7 ml_ of lysis buffer [50mM Tris; 25% Sucrose; 2 mg/nnL lysozyme; 0.05 mg/mL Lysostaphine; pH 7.5] and 100 L of 2 g/mL of boiled RNase A. Incubate 45 min at 37°C. Spin 10 min at 5000 xg. Resuspend the pellet in 3852 L of water, 300μί of EDTA,NA<sub>2</sub> 250 mM pH 8.0 and 300μί of SDS 10% (v/v). Agitate vigorously. Add 10 mL of phenol, equilibrated at pH 8.0. Agitate vigorously. Spin 5 min at 5000 x g. The upper aqueous phase undergoes a second extraction with 10mL of phenol/chloroform (1/1 ). Eventually repeat that step. Precipitate the DNA with 3 volumes of absolute ethanol. Save the precipitate and move it into a new tube. Wash with 70% ethanol (v/v) and spin 5min at 5000 x g. Repeat that step. Dry the DNA pellet. Dissolve in 300μί of TE buffer. Store at -20°C. </p><p id="p0103" num="0103">DNA amplification by Polymerase Chain Reaction (PCR) </p><p id="p0104" num="0104"> Assemble the reaction in ice, in that order : 35.5 L of MQ water, 10 L of PCRx5 buffer (which contains 7.5mM MgCI2), 1 μΙ_ of 0.2mM dNTP, 1 μΙ_ of each 
<!-- EPO <DP n="16"/>-->
 corresponding 25μΜ primer solutions (forward and reverse), 1 μΙ_ of the corresponding S. aureus total DNA (about 100 g) and 0.5μΙ_ of the DNA polymerase (Phusion High Fidelity DNA polymerase). PCR cycles for the amplification of the SEs genes are shown in the table 4 below. </p><p id="p0105" num="0105"><img id="imgf000016_0001" he="45" wi="122" file="imgf000016_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0106" num="0106"> Control of PCR product on agarose gel (1 % w/v) </p><p id="p0107" num="0107"> The agarose is dissoluted in TBE buffer x1 (89mM Tris-borate, 2mM EDTA, pH 8.0) by heating. Ethidium Bromide is included in the gel matrix at 0.5pg/ml_ to enable fluorescent visualisation of the DNA fragment under UV light (254 nm to 300 nm). The migration occurs at 110V during about 1 h. </p><p id="p0108" num="0108"> Electroelution of the PCR product in low melting point agarose gel 1 ,8% at</p><p id="p0109" num="0109">100V </p><p id="p0110" num="0110"> Make a phenol/chloroform extraction, then one ether extraction. Add 3μΙ_ of 5M NaCI and precipitate the DNA with ice-cold absolute ethanol. Wash the pellet with 70% ethanol (v/v) and let dry. Resuspend the DNA in TE and store at -20°C. </p><p id="p0111" num="0111">Ligation of the insert in the plasmid </p><p id="p0112" num="0112"> Restriction hydrolysis </p><p id="p0113" num="0113">Assemble in a Eppendorf tube: 15μΙ_ of the restriction enzyme buffer x10, 110μΙ_ of water, 20μΙ_ (10μg) of the plasmid or insert from PCR and 5μΙ_ of the corresponding enzyme restriction. Incubate 2h at 37°C. Add 6μΙ_ of 250mM EDTA pH8.0. Make a phenol extraction, keep the aqueous phase (upper phase). Make three ether extractions, keep the aqueous phase (lower phase). Add 3μΙ_ of 5M NaCI and 400μΙ_ of ice-cold absolute ethanol. Spin 5 min at 7 000 x g at 4°C, and discard the supernatant. Wash the DNA pellet with 70% ethanol (v/v), spin and discard the supernatant. Dry the DNA pellet. Continue to the following step : plasmid dephosphorylation. </p><p id="p0114" num="0114"> Plasmid dephosphorylation </p><p id="p0115" num="0115">To the dried DNA pellet, add 134μΙ_ of MQ water, 15μΙ_ of the buffer x10 and 1 μΙ_ of the CAIP enzyme. Incubate 1 h at 37°C. Add the same volumes and re- incubate 1 h at 37°C. Add 12μΙ_ of 250mM EDTA pH 8, vortex. Add 250μΙ_ of phenol. Vortex and incubate 10 min at 65°C. Vortex and re-incubate 10 min at 65°C. Discard the phenol. Make a phenol/chloroform extraction, then four ether 
<!-- EPO <DP n="17"/>-->
 extractions. Add 3μΙ_ of 5M NaCI and precipitate the DNA with ice-cold absolute ethanol. Wash the pellet with 70% ethanol (v/v) and let dry. Resuspend the DNA in 125μΙ_ of TE and store at -20°C. </p><p id="p0116" num="0116"> Ligation of the plasmid and the DNA fragment </p><p id="p0117" num="0117">In a final volume of 15 μΙ_, assemble ligase buffer; a molar ratio insert/vector of 3 to 5 and 0.2U of T4 DNA ligase. Incubate 16h at 14°C. </p><p id="p0118" num="0118">Transformation of competent bacteria with the ligation product </p><p id="p0119" num="0119"> Preparation of competent cells </p><p id="p0120" num="0120">From 3ml_ of 2xTY preculture, incubate a 100ml_ culture of E. coli XL1 Blue at</p><p id="p0121" num="0121">37°C under 200rpm shaking in the same medium. When OD<sub>6</sub>oonm reach 0.5 to</p><p id="p0122" num="0122">0.7, spin 10min at 2500 x g. Resuspend the pellet in 10ml_ of 50mM CaCI<sub>2</sub>.</p><p id="p0123" num="0123">Leave the bacteria 30min at 4°C, then spin 10min at 2500 x g at 4°C. Resuspend the pellet in 2.5mL of 50mM CaCI<sub>2</sub>. </p><p id="p0124" num="0124"> Transformation of bacteria by the thermal shock method </p><p id="p0125" num="0125"> Add 4μΙ_ of ligation product to 150μΙ_ of competent E. coli XL1 Blue cells.</p><p id="p0126" num="0126">Incubate 40min at 4°C, then a thermal shock of 2min at 42°C. After 2min of chilling at 4°C, spread out the preparation on TYA plate and incubate at 37°C overnight. </p><p id="p0127" num="0127">Control of ligation </p><p id="p0128" num="0128"> Mini preparation of plasmid DNA from E.coli </p><p id="p0129" num="0129">Inoculate a 2x TYA medium (3 mL) with an isolated colony and grow overnight at 37°C. Pellet cells at 12 000 xg for 30 sec. and discard the supernatant. Add 100μΙ_ of TEG buffer [25mM Tris, 50mM glucose, 10mM EDTA, pH 8.0] and resuspend cells. Add 200μΙ_ of Alkaline Lysis Buffer [0.2N NaOH, 1 % SDS], mix by inverting 5-6 times. Add 150μΙ_ of 3M Potassium Acetate (pH 5.5). Spin 10min at 12 000 x g. Transfer 400μΙ_ of supernatant to a new tube containing 1 mL of 24:1 Chloroform :lsoamyl Alcohol (CHCl<sub>3</sub>:IAA) and mix by inverting. Spin at 12 000 x g for 10 min. Transfer aqueous phase to 800μΙ_ of ice-cold absolute ethanol. Precipitate at -20°C for at least 30min. Spin at 7 000 x g for 10 min. Discard the supernatant and wash the pellet with 1 mL 70% ethanol (v/v), then 1 mL 95% ethanol (v/v). Discard ethanol and dry the pellet (air-dry). Dissolve in 40μΙ_ of TE containing 20Mg/ml_ of RNase A (Ribonuclease A SERVA®). Store at - 20°C. </p><p id="p0130" num="0130"> Control of ligation product by agarose gel electrophoresis </p><p id="p0131" num="0131">DNA minipreps are digested by the restriction enzyme corresponding to the insertion sites. The restriction product is then analyzed by agarose gel electrophoresis. 
<!-- EPO <DP n="18"/>-->
 Maxi preparation of DNA by chromatography (Plasmid Combi kit, Qiagen) Inoculate 100mL of 2x TYA medium with transformed bacteria and grow overnight at 37°C. Spin 10 min at 5000 x g. Resuspend the cells in 6ml_ of P1 buffer. Transfer the solutions into ultracentrifugation tubes. Add 6ml_ of P2 buffer in order to lyse the bacteria. Incubate 5 min and add 6ml_ of P3 buffer (SDS is precipited and the mixture is becoming viscous). Leave the medium 5min at room temperature then spin 40min at 25 000 x g at 4°C in angular rotor (Ti 60 - Beckman). Supernatant is then used for the chromatography. </p><p id="p0132" num="0132"> Equilibrate the anions exchange column (DEAE-cellulose groups) with 10mL of QBT buffer. Apply the supernatant to the column and then wash with 2 x 10ml_ of QC buffer. Eluate the DNA with 7ml_ of QF buffer. Add 20ml_ of ethanol and spin 10min at 5000 xg at 4°C. Wash the pellet with 70% ethanol (v/v). Let the pellet dry and resuspend in 350 L of TE buffer. Add 350 L phenol, shake vigorously and spin 5min at 5000 x g. The upper phase, containing the DNA, undergoes another phenol extraction. Followed four ether extractions, in order to get rid of phenol in the aqueous phase. Precipitate the DNA by adding 15 L of 5M NaCI and 1 mL of ice-cold absolute ethanol. Wash the pellet with 70% (v/v) ethanol. Resuspend the dried pellet in a necessary TE volume to get a DNA concentration of I pg/pL. </p><p id="p0133" num="0133"> Control of the insertion direction of the fragment </p><p id="p0134" num="0134"> The insertion direction of the fragment of interest in the vector is checked by sequencing, with the help of vector specific primers. </p><p id="p0135" num="0135"> The surexpression of the SE is estimated by GST enzyme activity titration (see below). </p><p id="p0136" num="0136"> Transformation of E.coli BL-21 with CaC^ treatment </p><p id="p0137" num="0137"> When ligation product are checked, E. coli BL21 cells can be transformed in order to get a significant sur-expression of SE. Make a 100mL 2xTY culture of E. coli BL21 , grow overnight at 37°C. Inoculate another 100mL 2x TY with the E. coli preculture. Let grow at 37°C until OD<sub>6</sub>oonm reach 0.5 to 0.7. Transfer the culture into a 50mL tube. Spin at 3000rpm 10 min at 4°C, discard the supernatant and add 10mL 50mM CaCI<sub>2</sub> to the pellet. Spin 10min, 3000rpm and at 4°C and discard the supernatant. Repeat that step : add CaC and spin. Dissolve the pellet in 5mL 50mM CaC^. Transfer 150 L of competent BL21 bacteria into a new eppendorf tube. Add 1 to 3 L (2ng) of transformed plasmid DNA. Transform bacteria by thermal shock method. Incubate 40min at 4°C, then 2min at 42°C. After 2min chilling at 4°C, spread out the cells on a 2x TYA plate. Incubate 24h at 37°C. 
<!-- EPO <DP n="19"/>-->
1.1. E. coli production of Staphylococcal enterotoxins (apart from SEP) </p><p id="p0138" num="0138">1.1.1. Preparation of bacterial lysate </p><p id="p0139" num="0139"> Two 2L flasks containing 400mL of 2xTYA medium are inoculated with 50 ml_ of a BL21 E. coli precultu re transformed by the pGEX-SE recombined strains, and incubated at 37°C under 200rpm shaking. When the OD<sub>6</sub>oonm reaches 0.4 to 0.6, fusion gene expression is induced with 0.2mM IPTG at 25°C overnight. Next day (18-22h), bacteria are centrifuged at 5000 x g during 10 min, at 4°C. The pellet is resuspended in 35ml_ of PBS-EDTA 1 mM buffer. Bacteria cells are then lysed by French Press (French Pressure Cell Press, SLM AMINCO<sup>®</sup>) under a 600 bars pressure. Bacterial lysate is centrifuged during 30 min at 29000 x g, at 4°C in a Ti60 rotor (Beckman). 1.1.2. GST enzyme activity titration </p><p id="p0140" num="0140"> GST enzyme activity leads to an estimation of the fusion protein concentration in the environment. GST catalyzes a transfer reaction of the GSH on the CDNB (Chloro-1 ,2,4 Dinitrobenzene) [Habig and al., J. Biol. Chem., 249 : 7130-7139, 1974] [20]. The product of the reaction absorbs at 340nm whereas the free CDNB has its maximum at 270 nm. The kinetic occurs in a spectrophotometric bowl. </p><p id="p0141" num="0141"> The enzyme buffer contains: </p><p id="p0142" num="0142"> H<sub>2</sub>O (Milli Q) 880μΙ_ x 10 reaction buffer (1 M potassium phosphate, pH 6.5) 100μΙ_ CDNB (100mM in Ethanol) 10μΙ_</p><p id="p0143" num="0143">Reduced Glutathion (100mM in distilled water) 10μΙ_</p><p id="p0144" num="0144">Sample or dilution 1/10, 1/20 10μΙ_</p><p id="p0145" num="0145">The bowl is then placed into the spectrophotometer and the absorption evolution is measured at 340 nm every minutes during 5 minutes against a negative control, containing all the components apart from the 10μΙ_ sample, replaced by 10μΙ_ of distilled water (even without GST, there is a degradation of the substrate). This reaction is linear until A<sub>3 0</sub>nm = 0.8. The GST concentration must be adjusted in order to get a linear reaction during 5 minutes. </p><p id="p0146" num="0146"> In those conditions, the GST concentration is proportional to the speed reaction (ΔΑ/min) in accordance to the following relation : </p><p id="p0147" num="0147"> [GST] = Vi x k x 1/d for 10μΙ_ of sample </p><p id="p0148" num="0148">where : [GST] in μg/mL </p><p id="p0149" num="0149"> Vi = (AOD<sub>34</sub>o - AOD<sub>34</sub>oblanc)/min </p><p id="p0150" num="0150"> 1/d = dilution inverse 
<!-- EPO <DP n="20"/>-->
 k = constant = 545 g.min.nnL </p><p id="p0151" num="0151">k is determined from a commercial GST solution (Sigma) with a known concentration. 1.1.3. Purification of the fusion protein to GST, by GSH affinity chromatography </p><p id="p0152" num="0152"> 4 ml_ of gel Gluthathione Sepharose 4B GSH™ (GE Healthcare) (capacity of 20mg of GST) is packed in a PD10 column (GE Healthcare). The column is equilibrated with 20 ml_ of buffer : PBS + EDTA 1 mM pH 7.5 per gravity. 16mg equivalent GST (determined by the GST titration above) are applied in batch and left 30 min at +4°C under smooth shaken. Then the gel is 10 min centrifuged at 200 x g and at +4°C, and washed in PD10™ with 20ml_ of PBS-EDTA. </p><p id="p0153" num="0153"> 6x2ml_ fractions are eluted with the buffer: Tris 50mM, GSH 30mM, NaCI 500mM pH8.0. Fractions with a significant DO280nm (&gt;0.2) are assembled, 10μΙ_ (20u) of PreScission protease™ (GE Healthcare) are added to cleave the fusion protein and incubation one night at +4°C. </p><p id="p0154" num="0154"> Note 1 : in order to avoid contaminations, a different column for each enterotoxin should be used. Gels should also need to be washed with 10ml_ of the solution: NaH<sub>2</sub>PO 30mM, NaCI 2M pH6.5 between two runs. </p><p id="p0155" num="0155"> Note 2 : For SEG+8 and SEH+5, the sample may be applied a second time on the column GSH affinity, after the protease action and desalting against PBS, in order to get a maximum of GST ; because those toxins are hardly separable of the GST, in the conditions of exchange ions chromatography presented below. </p><p id="p0156" num="0156">1.1.4. SEs purification by exchange cations chromatography </p><p id="p0157" num="0157"> After the PreScission protease™ action, the sample is diluted at 40ml_ with 10mM of start buffer containing 40mM (MES or Hac) adjusted with NaOH (see table 5 below) and then dialyzed against that buffer during 2h at + 4°C , with a Spectra Porl™ membrane (Spectrum Laboratories) with a nominal molecular weight limit from 6 to 8000 Da. Then the sample is completed with 30mM MES pH5.7 [from MES 500mM pH5.7] and with 3mM DTT [from DTT 1 M]. After 5 min centrifugation at 5000 x g at +4°C, different samples are applied on a 6ml_ ReSource S™ or MonoS™ column (GE Healthcare), equilibrated in start buffer. After column washing, elution is made by a linear gradient of NaCI, supplied by the end buffer, i.e. start buffer + 1 M NaCI. The NaCI gradient slope goes from 0 to 300 mM maximum in 63 ml_ (flow rate 4mL/min). </p><p id="p0158" num="0158"> Note: between two runs and for each SE, the gel is washed with 2ml_ de NaOH 0.5M. 
<!-- EPO <DP n="21"/>-->
 Table 5 </p><p id="p0159" num="0159"><img id="imgf000021_0001" he="34" wi="154" file="imgf000021_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0160" num="0160"> MES : 2-(N-Morpholino)ethane - sulfonic acid </p><p id="p0161" num="0161">Hac : acetic acid </p><p id="p0162" num="0162">DTT : 1 ,4 Dithiothreitol </p><p id="p0163" num="0163"> Note: Exchange ions separation shows different forms (enterotoxins found in several elution peaks), the prevalent form is kept. </p><p id="p0164" num="0164"> Toxins are stored at -80°C in aliquots of 2ml_ maximum. </p><p id="p0165" num="0165"> The purity is estimated in SDS-PAGE on a Phast SystemT<sup>M</sup> apparatus following the instructions of GE Healthcare. Briefly, 500ng in 1 μΙ_ of SE (50μΙ_ denatured in SDS 2.5% and β-mercaptoethanol) are applied on a PhastGel™ Gradient 10-15 and after electrophoretic migration, the gel is colored with blue coomassie (PhastGel Blue R). </p><p id="p0166" num="0166">1.2. SEP production </p><p id="p0167" num="0167"> Some troubles appear upon the expression of the sed gene, that changed the protocole to an antigen purification from a referred strain of Staphylococcus aureus. SED is purified from S. aureus (87109 (FRI1157M) of the Institut Pasteur, Mrs Dr Debuyser collection) : </p><p id="p0168" num="0168"> - BHI culture </p><p id="p0169" num="0169"> From a preculture (6H), twelve 2L flasks containing 200 ml_ of BHI are inoculated with 400μΙ_ and incubated at 37°C under 250rpm overnight (15-18H). Bacteria are discarded by centrifugation at 7 000 x g 10min at +4°C. </p><p id="p0170" num="0170"> - Supernatant precipitation with ammonium sulfate </p><p id="p0171" num="0171"> The supernatant is precipitated with solid ammonium sulfate (Sigma) : 667g to 1 L (90% of saturation) overnight (20-24H) at +4°C </p><p id="p0172" num="0172"> - Capture by cations exchange chromatography at pH5.7 SP Sepharose FF gel. </p><p id="p0173" num="0173"> After centrifugation, the pellet is dissolved with 100ml_ of water and dialysed in a SpectraPorl™ membrane (Spectrum Laboratories) first 2H at +4°C against 4L of water then against 2L of MES 10mM pH5.7. The sample is then completed to 30mM MES pH5.7 with MES 500mM pH5.7 solution and to 3mM DTT with a 1 M solution and centrifugated at 5000 x g 5 min at +4°C. The sample is applied on a 50ml_ SP Sepharose FF™ in a XK26 column (GE Healthcare) equilibrated with MES 40mM + DTT 1 mM, pH5.7 buffer. After column washing, 
<!-- EPO <DP n="22"/>-->
 elution is made by direct application of a MES 40mM + DTT 1 mM + 300mM NaCI, pH5.7 buffer. </p><p id="p0174" num="0174"> - Cations exchange chromatography at pH 5.7 Ressource S™ or MonoS™ column </p><p id="p0175" num="0175"> After the first exchange chromatography, the sample is dialysed again in the same conditions as above. Then, it is applied on a 8 ml_ MonoS™ Tricorn column (GE Healthcare) equilibrated in the same start buffer as above. After washing, elution is made by a linear gradient of NaCI in the same end buffer. The NaCI gradient slope goes from 0 to 160mM in 60 ml_. </p><p id="p0176" num="0176"> - Hydrophobic interactions chromatography at pH 7.0 Source-Phenyl gel. </p><p id="p0177" num="0177"> This step is delicate, SED highly hydrophobic is barely holded by the column. Now the pH of the sample is adjusted to 7,0 with a K<sub>2</sub>HPO<sub>4</sub> 1 .5M solution. Finally, the phosphate concentration of the sample is 350mM (KH<sub>2</sub>PO<sub>4</sub> 1 ,5M pH7.0) with 1 .7M ammonium sulfate ((NH<sub>4</sub>)2SO<sub>4</sub> 3M pH7,0). The sample is applied on a 1 ml_ Resource S™ or MonoS™ PHE column (GE Healthcare) equilibrated in KH<sub>2</sub>PO<sub>4</sub> 50mM + 1 .7M (NH<sub>4</sub>)2SO<sub>4</sub> + DTT 1 mM, pH7.0 buffer. After a short column washing with 3 ml_, elution is made by a linear decreasing gradient of ammonium sulfate, supplied by the end buffer: KH<sub>2</sub>PO<sub>4</sub> 50mM + DTT 1 mM pH7.0. The gradient slope goes from 1700mM to 0 in 10mL. </p><p id="p0178" num="0178"> - Storage </p><p id="p0179" num="0179"> Several runs of SED purification are put together (~4mg) and after dialysis, SED is concentrated on a MonoS column as above. The toxin is stored at -80°C after checking the purity on SDS PAGE as above. </p><p id="p0180" num="0180"> SED is recognized by the Oxoid SET RPLA™ kit (following the Oxoid instructions). </p><p id="p0181" num="0181"> Enterotoxins A, B, C, D, E, G, H, and I are kept inside a box placed in a -80°C freezer, located in a secured room. Amounts of enterotoxins stored and removed are recorded in a saved file and on a paper signed by the project responsible, all kept locked. A statement to the AFSSAPS for the B enterotoxin of Staphylococcus aureus is made. Every wild and recombinant microorganisms (even if they should be induced to get a toxin expression) are strictly controlled and used under a microbiological security post. Microorganisms used and toxins amounts which have to be used by the experience are denatured and sterilized, then confined on SharpSafe boxes before being evacuated to the Institute DASRI. Toxins amounts used and rejected are always less than 1 mg. </p><p id="p0182" num="0182">EXAMPLE 2: ANTIBODIES ANTI-8SEs ORIGINS </p><p id="p0183" num="0183">2.1. Procurement and affinity purification of the antibodies 
<!-- EPO <DP n="23"/>-->
 2.1.1. Generation of toxoids </p><p id="p0184" num="0184"> The 8 SEs (1 to 2 mg/mL) were turned into a toxoid by a 60mM or 330mM formalin treatment during 48H at 37°C in buffer : 50mM NaH<sub>2</sub>PO<sub>4</sub> + 150 mM NaCI pH 7.5 [protocol inspired from the thesis of M. PIEMONT or inspirited from Gampfer and al. [Vaccine, 20 : 3675-3684, 2002] [21 ]. The excess of formaldehyde was discarded by desalting on PD 10™ column (following the instructions of GE Healthcare) against PBS and the toxoids were stored at -20°C. During a second immunization drive, the 8 SEs were treated with 1 % formol [inspirited from Gampfer, 2002, fore-mentioned] [21 ] in order to get bigger immune-serum stocks and antibodies for SEH and SEI with a better affinity. For each SE, two New-Zealand rabbits were injected in subcutaneous with 50 g/500 L (apart from SED: 25 g then 100 g) with the complete Freund's adjuvant to start and then the incomplete formulation was used. </p><p id="p0185" num="0185">2.1.2. Toxoids preparations for injection </p><p id="p0186" num="0186"> Animals were immunized with 10 to 200 g per rabbit (50 g in a first generation of antibodies). Separately, the antigens were emulsified in a 1 :1 mixture of complete or incomplete Freund's adjuvant (CFA or IFA) and PBS with a 2ml_ syringe and a 1 .1 mm needle. Rabbits were shaved off and the preparations were injected with 0.7mm needles in three subcutaneous sites with 500μΙ_. Three booster immunizations were given at about 3-weeks intervals (for a second generation of antibodies IFA was used after the first injection). 2.1.3. Collect of sera </p><p id="p0187" num="0187"> Before the rabbits were bled, a sample of veinous blood from the ear was taken, about 500μΙ_. The sera was used in an Ouchterlony precipitation test. Briefly, in a plate with 0.6% agar in PBS, 40μΙ_ of sera or 40μΙ_ of SE at 150μg/mL were put into 2 wells separeted from 1 cm. After overnight incubation at +4°C, a line of precipitation was considered like a hyper- immunisation. After that, rabbits were bled of 35ml_ maximum under anesthesia : ketamin (20-40mg/kg) and xylazin (3-5mg/kg) [Borkowski and al., Clin. Tech. Small Anim. Pract., 14.(1 ): 44- 49, 1999] [22] at the ear artery with a vacuum pump device. If necessary, the rabbits were killed with Dolethal™. After overnight blood clot retraction at +4°C, sera were centrifuged 5000 x g 5 min and filtered (0.45μηη), and stored at -80°C by 10 mL fractions. </p><p id="p0188" num="0188"> Antibodies were purified by affinity on an activated "HiTrap NHS" support, where a native SE had been immobilized by injection-chromatography (Elution 
<!-- EPO <DP n="24"/>-->
 buffer: CitrateNa 0.1 M + NaCI 0.2 M, pH 2.5, then neutralization at pH 7.5 with Na<sub>2</sub>CO<sub>3</sub> 1 M). </p><p id="p0189" num="0189">2.1.4. Affinity purification of antibodies anti-SE </p><p id="p0190" num="0190"> The Akta Purifier™ device (GE Healthcare) and Hi-TrapNHS gel 1 ml_ (GE</p><p id="p0191" num="0191">Healthcare) were used wherein antigen corresponding to the antibody to purify was immobilized (see GE Healthcare protocol, "Ligand coupling procedure for HiTrap NHS-activated HP") (see table 6 below). </p><p id="p0192" num="0192"> Table 6 </p><p id="p0193" num="0193"><img id="imgf000024_0001" he="69" wi="141" file="imgf000024_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0194" num="0194"> The column was equilibrated with 10ml_ of PBS with a flow rate of</p><p id="p0195" num="0195">1 mL/min. The serum provided by the hyper-immunized rabbit, was centrifuged 5min at 5000 x g, and 5ml_ of serum were applied at the flow rate of 0.5mL/min. The column was washed with PBS. The antibodies were evaluated with citrate buffer [0.2M NaCI, 0.1 M citric acid, pH 2.5], at a flow rate of 1 mL/min. Fractions were then neutralized to pH 8 with 1 M Na<sub>2</sub>CO3 pH 9.5. The OD<sub>2</sub>80nm was measured. Fractions with a significant OD<sub>2</sub>80nm (&gt;0.2) were assembled. Antibodies were then dialyzed against 2L of 30mM NaH<sub>2</sub>PO , 100mM NaCI, pH 7.3 at 4°C overnight. </p><p id="p0196" num="0196"> The antibodies purified by affinity were frozen and stored at -80°C at a minimal concentration of 1 mg/mL. </p><p id="p0197" num="0197">2.2. Specificity of affinity purified antibodies and achievements of mono SE-specific antibodies 2.2.1. DOT-BLOT </p><p id="p0198" num="0198"> A piece of nitrocellulose (Protan <sup>BA83TM</sup> 0.22μηη Schleicher et Schuell) of about 7x3cm was cut. 1 L, i.e. 10ng, of each SE (stock solutions at 10pg/nnL) and a blank (BSA) were put and left to dry several minutes. The membrane was 
<!-- EPO <DP n="25"/>-->
 drenched (~20ml_) in the blocking buffer [PBS, 5% skimmed milk(w/v)], left at 4°C overnight, then washed with PBS + 0.05% Tween20 5min by immersion. The immunoabsorbed Ab antiSE, which the specificity is to check, was added at I pg/mL in 20ml_ of PBS + 0.05% Tw20 + 1 % skimmed milk and left 2h under smooth shaken, then washed 3 times. Goat Ab-POD anti-rabbit IgG purified by affinity (Sigma A6154), was added at a 1/800 dilution in the same buffer that primary Ab and incubated in the same conditions, then washed 3 times. The reaction was revealed according to the Opti 4 CN™ kit instructions (BioRad) : 9ml_ of water, 1 ml_ of the kit buffer and 0.2ml_ of the kit 4 CN, for 30 min max., depending on the blank. The membrane was washed with water several times and finally scanned. </p><p id="p0199" num="0199">2.2.2. Depletion of antibodies already affinity purified </p><p id="p0200" num="0200"> The HiTrap™ gel (1 ml_) with an antigen (namely an immunization- unrelated staphylococcal enterotoxin) immobilized responsible for the cross reaction was chosen. The gel was equilibrated with 5 to 10 mL of PBS on AktaPurifier™ device (GE Healthcare) at flow rate I mL/min. An amount of Ab was applied from one run of affinity chromatography (1 ml_ of gel), at a flow rate 0.5mL/min, and Ab which passed through the immunoabsorption column were collected. Ab eluated by the citrate buffer were removed, about 10ml_ at flow rate I mL/min. The column was washed with 5 to 10 mL of PBS. The column was stored in PBS + NaN3 0.1 % at 4°C. After control of their specificity (by DOT- BLOT) against the immunogen and/or cross reactivity with an antigen (namely an immunization-unrelated staphylococcal enterotoxin), depleted Ab were stored at -80°C at a concentration of 1 to 3 mg/mL. </p><p id="p0201" num="0201"> If a cross reaction was still detected, the depletion step was again implemented as above described against the same antigen or another antigen as above defined (which is still not the immunogen) until obtaining the monospecificity of depleted Ab. The order of successive columns could be determined by one skilled in the art according to the extent of each cross reaction detected, namely from the stronger cross reactivity to the weaker cross- reactivity. </p><p id="p0202" num="0202"> Step-by-step immunoabsorptions / depletions in the exact order of the successive columns made on the affinity purified antibodies are shown in the table 7 below. </p><p id="p0203" num="0203"> Note 1 : For IgG, DO280 = 1 ,0 means a concentration of 750 g/mL. </p><p id="p0204" num="0204"> Note 2 : Concentration of Ab is possible by ultrafiltration, using Amicon® 4mL or 15mL, cut off 10kDa units ( according to Millipore™ instructions). 
<!-- EPO <DP n="26"/>-->
 Table 7 
<img id="imgf000026_0001" he="15" wi="169" file="imgf000026_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 </p><p id="p0205" num="0205"> Those depleted antibodies were frozen in the buffer: NaH<sub>2</sub>PO<sub>4</sub> 30 mM + NaCI 100 mM, pH 7.3. </p><p id="p0206" num="0206"> Such antibodies may be used downstream for several kinds of applications (beads-based multiplex technologies, chip-based protein microarray, immunocapture coupled to MALDI-TOF, etc....). </p><p id="p0207" num="0207">EXAMPLE 3: COUPLING OF ANTI-SEs ANTIBODIES TO LUMINEX MICROSPHERES AND BIOTIN </p><p id="p0208" num="0208">3.1. Beads sensitization with the depleted antibodies anti-SEs </p><p id="p0209" num="0209"> Each depleted antibody anti-SEs was combined with a microsphere of an unique color-code according to the table 8 below. 3.1.1 Protocol (inspired from Amine coupling kit of BioRad ref 171-</p><p id="p0210" num="0210">406001) </p><p id="p0211" num="0211"> For each SE, 19.5 x 10<sup>6</sup> carboxylated beads were activated at pH6.0 (Buffer: MES 0.1 M + NaCI 0.15 M pH 6.0) by 50mg/mL of EDC with sNHS during 30 minutes under shaking at room temperature. After wash by centrifugation 10 min at 10 000 x g, 360 g of depleted antibodies (without NaN<sub>3</sub> and Amine) were added, i.e. 18.5 g for 1 million of beads, and were incubated in PBS during 2H under shaking, at room temperature and in darkness. After wash, free sites were blocked with ethanolamine (Buffer: ethanolamine 50 mM + NaCI 150mM, pH 8.5) during 30 minutes. Then the blocking buffer was replaced by the storing one: PBS + NaN<sub>3</sub> 0.05% (p/v). The storage was made at +4°C and in darkness during several months after assembling in one fraction the 8 types of beads at 1 x10 beads of each color region/mL. </p><p id="p0212" num="0212"> Finally, the fluorescence of the coupled beads was measured by the BioPlex- 100™ with biotin-coupled goat antigen (Sigma), rabbit anti-lgG and SEPE. The final suspension concentration was determined by a 1 mm<sup>3</sup> hemacytometer. 
<!-- EPO <DP n="27"/>-->
 Acquired results for the validation of the beads set </p><p id="p0213" num="0213"> Table 8 </p><p id="p0214" num="0214"><img id="imgf000027_0001" he="81" wi="155" file="imgf000027_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0215" num="0215"> According to the supplier BioRad, a bead was sufficiently coupled if UFI SEPE &gt; 2000 and UFI blank &lt; 100. This was the case for the 8 types of beads. </p><p id="p0216" num="0216">3.2. Biotin coupling of antibodies </p><p id="p0217" num="0217"> Like the secondary antibodies, the simply affinity purified antibodies (8AbBt(X)) individually coupled to biotin were used. The test specificity was made by the primary antibody immobilized on the beads, since it ensured the antigens selection and all the test specificity. </p><p id="p0218" num="0218"> The 8 depleted Ab individually biotin-coupled (AbBt(-)) were also used for the need of the test specificity (see below). That specificity was compared to the one of AbBt(x); the specificity deviation was not significant, but the sensibility seemed to be lightly strengthened by the use of affinity purified antibodies, for a low production cost. </p><p id="p0219" num="0219"> Protocol of biotin coupling: </p><p id="p0220" num="0220"> The protocol was unchanged whatever the Ab chosen (without NaN<sub>3</sub> and Amine). 200pg of Ab at 1 mg/ml_ in PBS were mixed to 10μΙ_ of sNHS-Lc-Bt (Molecular Probes) at 2.67 mM during 2H at room-temperature, i.e. a initial molar ratio [Bt] / [Ac] = 20. Free biotin was blocked by 10μΙ_ of ethanolamine 100mM, pH 7.5 during 30min at room-temperature, then 5.5μΙ_ of NaN<sub>3</sub> were added at 2%, i.e. a final concentration of 0.05% (p/v). The AbBt(-) and the AbBt(x) on either side were assembled in 2 fractions (x) and (-) only after the specificity test (see below). Each fraction was aliquoted and stored at -20°C at 100μg mL. 
<!-- EPO <DP n="28"/>-->
 EXAMPLE 4 : GENERAL INSTRUMENTAL PROTOCOL : LUMINEX xMAP TECHNOLOGY </p><p id="p0221" num="0221">As a preamble, a reminder of the protocol of BioPlexl OO™ utilization : - A plan of the 96-wells plate for a maximum of 31 samples was drawn, made in duplicate (with 1 blank for each type of cheese matrix), 12 standards (from 16384 to 8 pg/mL, 2 in 2 dilution), 3 identical standard blanks and 2 controls at 4000 and 400pg/mL of the 8 SEs (those two points could be replaced by external control of the laboratory). Every points were in duplicate. </p><p id="p0222" num="0222">- Antigen aliquot was defrosted. </p><p id="p0223" num="0223"> - From the stock suspension of beads coupled to the 8 depleted Ab anti-SEs at 1 . 10<sup>6</sup> beads/region/mL, a final solution at 10<sup>5</sup> was prepared and 50 μί were splitted out in a 96-wells multiscreen plate (Millipore), i.e. 5000 beads/region/well. </p><p id="p0224" num="0224">- Washing by aspiration with the manifold pump: 2 to 3 inches Hg of depression then 100μί of TBS (Tris-HCI 40 mM + NaCI 140 mM, pH 7.5) were added and re-aspirated. </p><p id="p0225" num="0225"> - 50 L/well of antigen (sample, standard, blank and control) were transferred according to the plate plan and incubated under high shaking (600) during 1 h30, at room-temperature and in darkness. </p><p id="p0226" num="0226"> - Then washed 3 times by aspiration. </p><p id="p0227" num="0227"> - 50 L/well of the 8Ab-antiSEs-Bt(x) solution (non depleted) were added at 0.25 g/mL in TBS and incubated 1 h, at room-temperature and in darkness.</p><p id="p0228" num="0228">- Then washed 3 times by aspiration. </p><p id="p0229" num="0229">- 50 L/well of 0.5 g/mL SEPE solution (stock solution at I mg/mL, Molecular Probes ref : S866) were added and incubated 15 min, at room-temperature and in darkness. </p><p id="p0230" num="0230"> - Then washed 3 times by inspiration. </p><p id="p0231" num="0231"> - Each well was resuspended in 125 L of TBS + Tween 20 at 0.05% and stirred 1 min. </p><p id="p0232" num="0232"> - The plate was read at the BioPlexl OO™ according to the BioRad instructions (calibration and start up). </p><p id="p0233" num="0233"> - Results were analyzed for each SE : the assays concentration was determined after subtraction of the cheese matrix blank, with the aid of the inverse function f-1 which is : 
<!-- EPO <DP n="29"/>-->

<img id="imgf000029_0001" he="30" wi="60" file="imgf000029_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0234" num="0234">x = concentration </p><p id="p0235" num="0235">y = response (Fl) </p><p id="p0236" num="0236">a = estimated response at infinite concentration </p><p id="p0237" num="0237">b = slope of tangent at midpoint </p><p id="p0238" num="0238">c = midrange concentration or midpoint </p><p id="p0239" num="0239">d = estimated response at zero concentration </p><p id="p0240" num="0240">g = asymmetry factor </p><p id="p0241" num="0241"> Note : Beads concentration (5000/SE/well) is chosen for a plate reading of</p><p id="p0242" num="0242">30 to 45 min. The sensibilization with 18.5 g of Ab/million of beads produces a satisfactory maximal signal (&gt;2000 UFI), apart from SEH and SEI which have a lower signal. 8 AbBt(x) and SEPE concentration produce the lowest limit of quantification (LOQ). </p><p id="p0243" num="0243">EXAMPLE 5 : TITRATION TEST VALIDATION </p><p id="p0244" num="0244"> Results exposed there concern the xMAP technology application for the 8SEs titration besides of cheese matrix. </p><p id="p0245" num="0245">5.1. Specificity </p><p id="p0246" num="0246"> The aim was to estimate the degree of cross-reaction between the primary depleted Ab coupled to beads on one hand, and the secondary biotin-coupled Ab in the other hand, towards the 8 SEs. </p><p id="p0247" num="0247">5.1.1 Modification of the protocol exposed in EXAMPLE 4. </p><p id="p0248" num="0248"> In that aim, those following ELISA sandwiches were made up : </p><p id="p0249" num="0249"> - A : beads 8Ab-antiSEs (depleted) + 1 SE / well + 8AbBt(x) + SEPE, with the Ag at about 19.6 ng/mL, a concentration equal to the S1 point (16.4 ng/mL) of the standard range (table 9). </p><p id="p0250" num="0250"> - B : beads 8Ab-antiSEs (depleted) + 8 SE / well + 1AbBt(x) + SEPE (table 10). </p><p id="p0251" num="0251"> For results analyzing, the net value of fluorescence (Fl-blk) was noticed every time. The specificity, expressed in %,was given by the ratio of the detected signal (Fl-blk) by the specific signal for each SE. </p><p id="p0252" num="0252"> - C : beads 8Ab-antiSEs (depleted) + 1 SE / well + 8AbBt (depleted) + SEPE, with the Ag at about 19.6 ng/mL , a concentration equal to the S1 
<!-- EPO <DP n="30"/>-->
 point (16.4 ng/mL) of the standard range (table 11 ). 5.1.2. Specificity - Results - Conclusions </p><p id="p0253" num="0253"> Table 9: ELISA specificity: A </p><p id="p0254" num="0254"> % QFA QFR QCr QFR QFF &lt;¾Ffi ¾FH SFI antiSEA (E E I B D) 100 0 0 0 0 0 0 0 antiSEB (C1 C1 G) 1 100 0 0 0 0 0 0 antiSECI (B B G) 1 0 100 0 0 0 0 0 antiSED (A A E) 0 0 0 100 0 0 0 0 antiSEE (A A 1 C1) 0 0 0 0 100 0 0 0 antiSEG (A B I C1) 1 0 0 0 0 100 0 0 antiSEH (B D) 2 0 1 1 0 0 100 0 antiSEI ( E C1 G B A) 0 0 0 0 0 0 0 100 Conclusion : the 8 depleted Ab anti-SEs did not produce significant cross- reaction between the 8 SEs. A depleted Ab immobilized to a bead, only fixed its own antigen. </p><p id="p0255" num="0255"><img id="imgf000030_0001" he="66" wi="141" file="imgf000030_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0256" num="0256"> Conclusion: B ELISA revealed cross-reactions with some SEs for the 8 simply affinity purified Ab anti-SEs. However, as the bead-immobilized depleted Ab were strictly specific, the simply affinity purified Ab as secondary Ab could be used. B ELISA also suggested a different immunoabsorption protocol from the one made up with the DOT BLOT results. 
<!-- EPO <DP n="31"/>-->
 Table 11 : ELISA specificity: C </p><p id="p0257" num="0257"> % SEA SEB SEC SED SEE SEG SEH SEI antiSEA (E E I B D) 100 0 0 0 1 0 0 0 antiSEB (C1 C1 G) 0 100 0 0 0 0 0 0 antiSECI (B B G) 1 0 100 0 0 0 0 0 antiSED (A A E) 0 0 0 100 0 0 0 0 antiSEE (A A 1 C1) 0 0 0 0 100 0 0 0 antiSEG (A B I C1) 1 0 0 0 0 100 0 0 antiSEH (B D) 1 0 0 0 0 0 100 0 antiSEI ( E C1 G B A) 0 0 0 0 0 0 0 100 </p><p id="p0258" num="0258">Conclusion: identical to the table A conclusion. </p><p id="p0259" num="0259"> Note: That type of specificity test did not announce any specific cross- reaction in cheese matrix, like with protein A. Such interactions with protein A could easily be circumvent by the addition of 10 pg/nriL aspecific rabbit IgG. </p><p id="p0260" num="0260">5.2. Sensibility and detection limits </p><p id="p0261" num="0261"> Aim: from the standard curve of the antigens titration, deduce the LOD (limit of detection) and the LOQ (limit of quantification). </p><p id="p0262" num="0262">5.2.1. Standard curve </p><p id="p0263" num="0263"> The reference concentrations (Cref) of the 8 SEs were obtained from spectrophotometry at DO280nm according to the Beer-Lambert law. The extinction coefficients (ε) used were those given by the server software http://expasy.org as Protparam (see table 12 below), according to the corresponding primary sequences (figure 2) : </p><p id="p0264" num="0264"> Table 12 </p><p id="p0265" num="0265"> SE SEA SEB SEC1 SEP SEE SEG SEH SEI ε en L.g<sup>"1</sup>.cm<sup>"1</sup> 0,725 0,779 0,915 1 ,021 0,736 0,912 0,964 0,727 </p><p id="p0266" num="0266"> 1 ml_ of a stock solution of the 8SEs at 6.55pg/ml_ has been prepared in TBS and frozen at -40°C. </p><p id="p0267" num="0267"> In TBS+Tween20+lgAasp [aspecific IgG, i.e. prepared from a non- immunized rabbit serum and affinity purified on Sepharose Fast Flow Protein G™ (GE healthcare)] Tris 40mM + NaCI 140 mM pH 7.5 + Tween 20 at 0.05% + aspecific rabbit IgG at l Opg/mL, purified on G protein (stock solution at 5200Mg/ml_). </p><p id="p0268" num="0268"> The stock solution of SEs was diluted at 1/100 with the same buffer, then a cascade dilution, 2 in 2 between 65.6 and 0.008 ng/mL. The standard range used was from 16.4 to 0.008 ng/mL, i.e. 12 points of measure. 
<!-- EPO <DP n="32"/>-->
 A non linear Logistic-5PL regression was made with StatLIA Immunoassays software of Brendan Scientific, included in BioPlex Manager 4.0. </p><p id="p0269" num="0269"> Results: Standards curves : Observed concentrations (Cobs) (Plates 100 to 104, i.e. n=5) see figures 3 and 4 : "averaged standard curves and series of assays 100 to 104. </p><p id="p0270" num="0270"> In theory, after several types of regression tested (linear, exponential, logistic,...), the type kept was the one that reflected the best the measured magnitude (y) depending of the explanatory variable (x). If the 12 points of the standard range of the test plates (100 to 104) were linked by two types of regression: one linear and the other non linear Biologistic-5PL; the look of the non linear Biologistic 5-PL regression explained better the y=f(x) evolution than a straight line. </p><p id="p0271" num="0271">5.2.2. Calculation of LOD (limit of detection), lower LOQ (limit of quantification) and AWR (assay working range). </p><p id="p0272" num="0272"> The aberrant points among the 6 blank wells were removed with the Grubbs test. </p><p id="p0273" num="0273"> LOD and lower LOQ were determined according to Soejima and al. [Int. J. Food Microbiol., 93(2) : 185-194, 2004] [23] (see table 13). </p><p id="p0274" num="0274"> If d was the estimated response at zero concentration and S the blanks standard deviation (n=6), then LOD = f-1 (d+3,3<sup>*</sup>S), with f-1 the inverse function of FI=f(conc), provided by StatLIA, and lower LOQ=f-1 (d+10<sup>*</sup>S). </p><p id="p0275" num="0275"> Results (plate 100 to 104, i.e. n=5) (see figure 5): </p><p id="p0276" num="0276"> Table 13 </p><p id="p0277" num="0277"><img id="imgf000032_0001" he="41" wi="143" file="imgf000032_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0278" num="0278"> That method did not include a higher limit of quantification, and was dependent of the blanks (base line). </p><p id="p0279" num="0279">5.3. Linearity of the titration : Cobs = F(Cref) </p><p id="p0280" num="0280"> Linearity of Cobs=f(Cref) tested on the 12 points of the standard range (n=5). Since R<sup>2</sup>&gt;0.99, the response could be considered as linear for indicated values (see the table 14 below). </p><p id="p0281" num="0281"> See Linearity of standard in figure 6. 
<!-- EPO <DP n="33"/>-->
 Table 14 
<img id="imgf000033_0001" he="23" wi="162" file="imgf000033_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/>
 </p><p id="p0282" num="0282"> Whatever PBS buffer or milk considered, strictly comparable values were obtained. EXAMPLE 6 : TITRATION OF THE 8 SEs IN DIFFERENT MATRIX </p><p id="p0283" num="0283">6.1. Protocol of matrix preparation </p><p id="p0284" num="0284"> It was adapted from the method of Macaluso and Lapeyre [Analusis, 28(7) : 610-615, 2000] [24], without the PEG 20 000 precipitation, and according to Soejima and al. [2004, fore-mentioned] [23] for the concentration by ultrafiltration and delipidation. </p><p id="p0285" num="0285"> Before hand, the 8 SEs were added to the matrix at 4 concentrations (640 - 320 - 160 - 80 pg/mL) likely to be found in contaminated cheese and which the lowest concentration was close to the lower LOQ (particularly for SEH and SEI). </p><p id="p0286" num="0286"> - 12.5g of munster (1 <sup>st</sup> price Auchan) were cut in small pieces and added to 25ml_ of water in a 50ml_ tube (PP) at room-temperature, stirred vigorously 15sec and grinded by UltraTurrax™ during 1 min. Freeze at -20°C for several days. </p><p id="p0287" num="0287"> - The day of the preparation, homogenates were defrosted and fluidized at 37°C during several min by shaking. Then the 8 SEs were added at 640 -</p><p id="p0288" num="0288">320 - 160 - 80 pg/mL in 4 different homogenates, the 5<sup>th</sup> is the "matrix blank", stirred vigorously 15s and left aside for 15 min at room- temperature. Caseins precipitation: </p><p id="p0289" num="0289"> Samples were acidified with HCI (~5M) until pH 3.5 (check pH with pH indicator sticks pH2 to 9 +/- 0.5, with Hac solution 0.2M pH3.8 as a positive control). The HCI volume added was written: about 800μΙ_ were necessary. Samples were stirred and centrifuged 10 min at 7000 x g, at room-temperature. 20ml_ of the supernatant were taken between the pellet and the cream and 50mM of Tris (1 ml_) and 1 mM of CaCI<sub>2</sub> (20μΙ_) were added then the pH was adjusted at 7.5 +/- 0,3 with NaOH (~2M) (pH to check with Lyphan® L669, with HEPES solution 0.5M pH 7.5 as a positive control). The NaOH volume was written: about 300μΙ_. </p><p id="p0290" num="0290"> The resulting solution was stirred and centrifuged 10min, room- temperature at 7000 x g. ~15ml_ of the supernatant were kept (it may be slightly 
<!-- EPO <DP n="34"/>-->
 cloudy). </p><p id="p0291" num="0291">Delipidation : </p><p id="p0292" num="0292"> 2ml_ of HCCI3 were added to each supernatant, stirred vigorously and centrifuged 10min at 7000 x g at room-temperature and the aqueous phase was kept. A disk of precipitation appeared between the two phases and the supernatant was unclouded. </p><p id="p0293" num="0293">Desalting by ultrafiltration : </p><p id="p0294" num="0294"> 4ml_ of each supernatant were placed in a ultrafiltration Amicon® 4</p><p id="p0295" num="0295">(Millipore™) system, with a nominal molecular weight limit of 10kDa, and centrifugated ~12min at 7500g at room-temperature (rotor 35°). The final volume was lower than 0.8ml_. The retentate was homogenized and the volume was adjusted to 4ml_ with TBS (Tris-HCI 40mM + NaCI 140mM pH 7.5). x5 concentration by ultrafiltration: </p><p id="p0296" num="0296"> Each retentate was re-centrifugated with the same filter unit, then homogenized and the volume was adjusted to 800μΙ_. That concentrate was more "viscous" than before 5x concentration. </p><p id="p0297" num="0297"> Tween 20 at 0.05% and rabbit aspecific IgG at 10pg/nnL were added to each sample, and frozen at -20°C. </p><p id="p0298" num="0298"> Titration of the 8 SEs were performed the day after according to the general instrumental protocol 4. 6.2. Eight SEs titration in Munster - Results - Conclusion 6.2.1. Recovery rate in different matrix </p><p id="p0299" num="0299"> On the plate 037, there were 10 points (16384 to 32pg/ml_, 2 in 2 of 7SEs(without SED)), prepared (in 50% of whole milk centrifugated and filtered on 0,45μηη or 50% Brain Heart Infusion) in TBS + Tween 20 0,05% + rabbit IgG l OOpg/mL. </p><p id="p0300" num="0300"> The bias % (Mu HCL) was obtained on Munster after caseins precipitation and delipidation (see also figure 7) In order to turn the LOQ per g of cheese down, the matrix was concentrated after caseins precipitation and delipidation : </p><p id="p0301" num="0301"> - Plate 101 : desalting then concentration as exposed in the matrix preparation protocole 6.1 (see also figure 8) </p><p id="p0302" num="0302"> - Plate 103 : ultrafiltration of 10ml_ for 1 h at 5000 x g at room-temperature with a nominal molecular weight limit of 300kDa to collect 6ml_ of filtrate, 
<!-- EPO <DP n="35"/>-->
 of which 4ml_were desalted and concentrated as exposed in the matrix preparation protocol 6.1 . (see also figure 8) </p><p id="p0303" num="0303"> - Plate 104 : ultracentrifugation of 10ml_ during 1 h or 3h at 100 000 x g (33300 t/min 50 Ti) then 4m L were desalted and concentrated as exposed in the matrix preparation protocol 6.1 . There were no significant differences between the results of 1 h or 3h of centrifugation. (see also figure 8) </p><p id="p0304" num="0304"> In the table 15 below, the relative bias (%) in relation to TBS+Tween+lgG in standard range was presented : </p><p id="p0305" num="0305"> Table 15 </p><p id="p0306" num="0306"><img id="imgf000035_0001" he="49" wi="138" file="imgf000035_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0307" num="0307"> ND : not determined </p><p id="p0308" num="0308"> If average biases were compared, the bias was mostly lower in whole milk than in munster or BHI. SEC showed an important difference between the milk and the munster, and that led to the problem of the protein stability in its secretion environment. SEI had always a high bias, probably due to the insufficient Ab sensibility of that generation. </p><p id="p0309" num="0309"> After concentration, for the 8 SEs absolute value of the biases raise compared with casein precipitation and delipidation : the inhibitory effect of the matrix raised with its concentration, whatever the conditions 101 , 103 or 104 which had the less bad result. </p><p id="p0310" num="0310">6.2.2 Proposal of the correction of the loss of 8Ses and lower LOD in Munster </p><p id="p0311" num="0311"> For all the SEs, an important negative bias has been evaluated, reflecting the inhibitor effect of the matrix. However, that bias could be corrected by a factor defined in the table below : (+/- s (standard deviation)) : 
<!-- EPO <DP n="36"/>-->
 After casein precipitation and delipidation </p><p id="p0312" num="0312"> Table 16 </p><p id="p0313" num="0313"> Cf ± s SEA SEB SEC1 SED SEE SEG SEH SEI</p><p id="p0314" num="0314">Correction 1.49 1.43 2.64 1.82 1.80 1.62 1.28 2.75 factor +/-0.13 +/-0.04 +/-0.08 +/-0.19 +/-0.18 +/-0.16 +/-0.15 +/-0.48 </p><p id="p0315" num="0315">Note : the concentration Cobs had been introduced regardless the LOQ. Then, due to a negative bias, for SEH and SEI, Cobs are lower than the LOQ for the 72pg/mL point, which did not have been deleted for that study. </p><p id="p0316" num="0316">Allowing the dilution factor of 1/3.3 from the matrix preparation and the negative bias correlated to Cf, a new LOQ per g of cheese could be revealed: LOQ pg/g = LOQ pg/mL x 3.3 x Cf (see the table 17 below). </p><p id="p0317" num="0317"> Table 17 
<img id="imgf000036_0001" he="15" wi="138" file="imgf000036_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0318" num="0318">After casein precipitation delipidation and concentration (plate 104 conditions) </p><p id="p0319" num="0319"> Table 18 
<img id="imgf000036_0002" he="23" wi="152" file="imgf000036_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 </p><p id="p0320" num="0320">Allowing the concentration factor of 5/3.3 resulting from the matrix preparation and the negative bias reflected by Cf<sup>*</sup>, a new lower LOQ per g of cheese could be revealed: Lower LOQ pg/g of cheese = lower LOQ pg/mL x 3.3/5 x Cf (see the table 19 below). </p><p id="p0321" num="0321"> Table 19 
<img id="imgf000036_0003" he="15" wi="137" file="imgf000036_0003.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 </p><p id="p0322" num="0322"> Overall, the lower LOQ per g of cheese drop after concentration, apart from SEC1 . But since Cf<sup>*</sup> &gt; Cf, the result uncertainty raises. </p><p id="p0323" num="0323">The depleted polyclonal antibodies developed here could be used in different tests, among which the Luminex™ technology. These antibodies conserved a high affinity and gathered the possibility to detect all SEs already designed to be responsible for collective food-born intoxications. 
<!-- EPO <DP n="37"/>-->
 EXAMPLE 7 : TITRATION OF SEA AND SED PRODUCED BY S. AUREUS IN CHEESE. This assay was carried out to test whether enterotoxins produced by different Staphylococcus aureus isolates could be detected in cheeses : Munster or Babybel®. </p><p id="p0324" num="0324">7.1. Strain 361 F </p><p id="p0325" num="0325">This strain produces SEA and SED often implicated in foodborne disease. Bacteria were added on the first day (DO) of cheese making at four different concentrations: 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, 10<sup>6</sup> colonies forming units per milliliter. Samples were collected at different days: </p><p id="p0326" num="0326"> D1 and D21 for Babybel® </p><p id="p0327" num="0327"> D1 and D15 for Munster. At D15, the heart (H) of the cheese and crust (C) were separated into two separate samples. </p><p id="p0328" num="0328"> The collected samples were extracted using the protocol described in 6.1 and titrated using the protocol described in 4. After correction for the extraction volume, the results were expressed as pg enterotoxin / g of cheese (n=3). </p><p id="p0329" num="0329">Munster </p><p id="p0330" num="0330"><img id="imgf000037_0001" he="74" wi="164" file="imgf000037_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0331" num="0331"> ND : not detected 
<!-- EPO <DP n="38"/>-->
 Babvbel® </p><p id="p0332" num="0332"><img id="imgf000038_0001" he="47" wi="164" file="imgf000038_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 This assay detected enterotoxins SEA and SED produced by S. aureus in cheeses from densities greater than 10<sup>3</sup> CFU/mL. The final titer increased with the bacterial count, the length of the maturing period and the two enterotoxins rather accumulated in the crust of Munster. 7.2. OTHER STRAINS </p><p id="p0333" num="0333">In the same conditions the production of other Enterotoxins (pg/g) in cheese (Munster and Babybel®) contaminated with S. aureus was tested but only at 10<sup>4</sup> CFU/mL (n=3). </p><p id="p0334" num="0334">Strain A79 : SEA+ and SEB+ 
<img id="imgf000038_0002" he="22" wi="158" file="imgf000038_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 
<img id="imgf000038_0003" he="21" wi="158" file="imgf000038_0003.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 </p><p id="p0335" num="0335">Strain P4 : SEC+, SEG+, SEH+ and SEI+ </p><p id="p0336" num="0336"><img id="imgf000038_0004" he="35" wi="158" file="imgf000038_0004.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0337" num="0337"> ND : not detected 
<!-- EPO <DP n="39"/>-->
 Babybel® D1 D21 </p><p id="p0338" num="0338"> SEC ND ND</p><p id="p0339" num="0339">SEG ND ND</p><p id="p0340" num="0340">SEH 69 ±22.5 416 ±8.9 </p><p id="p0341" num="0341"> SEI ND ND</p><p id="p0342" num="0342">ND : not detected </p><p id="p0343" num="0343">Strain A67 : SEE+ </p><p id="p0344" num="0344"><img id="imgf000039_0001" he="61" wi="158" file="imgf000039_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0345" num="0345"> ND : not detected 
<img id="imgf000039_0002" he="15" wi="158" file="imgf000039_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 The search for the production of enterotoxins in cheese from the five strains above showed that this production was dependent on the strain. If the test detected SEA, SEB, SED, SEE and SEH, it did not reveal clearly the production of SEC, SEG and SEI. EXAMPLE 8: TITRATION OF THE 8 SES IN MEAT AND SAUCE </p><p id="p0346" num="0346">Four foods were selected based on animal proteins involved in the foodborne diseases : duck mousse (DM), liver mousse of pork (PM), custard sauce (CS) and pepper sauce (PS). </p><p id="p0347" num="0347">8.1. Protocol of matrix preparation </p><p id="p0348" num="0348">This protocol was adapted from that used for the cheese described in 6.1 with modifications: </p><p id="p0349" num="0349"> 8 SEs were added to the matrix at 800 pg/mL and a blank was prepared for each food. 
<!-- EPO <DP n="40"/>-->
 Precipitation of casein is performed only for pepper sauce. </p><p id="p0350" num="0350"> In all cases, after centrifugation 10 min at 7000 x g, the cloudy supernatants were non-filterable later during the washing steps of the ELISA. Also, lipids were extracted with two volumes of chloroform. After centrifugation, a disk of precipitation appeared between the two phases and the supernatants were unclouded and ready for desalting and concentration by ultrafiltration. </p><p id="p0351" num="0351">8.2. Eight SES titration - Results - Conclusion </p><p id="p0352" num="0352"><img id="imgf000040_0001" he="39" wi="154" file="imgf000040_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0353" num="0353">Bias (%) after concentration (x5) </p><p id="p0354" num="0354"><img id="imgf000040_0002" he="35" wi="155" file="imgf000040_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0355" num="0355">The bias after desalting was lower than after concentration. </p><p id="p0356" num="0356"> Remark: generally, samples were more viscous after concentration, especially pepper sauce. </p><p id="p0357" num="0357"> For several samples the bias was positive : duck mousse for example, this bias could come from a poor dissemination of toxins at the step of contamination. SEI had always a high bias, probably due to the insufficient Ab sensibility of that generation. </p><p id="p0358" num="0358">The depleted polyclonal antibodies developed here could be used in different tests, among which the Luminex™ technology. These antibodies conserved specificity and affinity and authorize the possibility to detect all SEs already designed to be responsible for collective food-born intoxications. 
<!-- EPO <DP n="41"/>-->
 List of references </p><p id="p0359" num="0359">1 . Jones and Kahn, J. Bacterid., 166 : 29-33, 1986 </p><p id="p0360" num="0360"> 2. Betley and Mekalanos, J. Bacterid., 170(1 ) : 34-41 , 1988 </p><p id="p0361" num="0361">3. Couch and al., J. Bacterid., 170 : 2954-2960, 1988 </p><p id="p0362" num="0362"> 4. Bayles and landolo, J. Bacterid., 171 : 4799-4806, 1989 </p><p id="p0363" num="0363"> 5. Dingues and al., Clin. Microbiol. Rev., 13 : 16-34, 2000 </p><p id="p0364" num="0364"> 6. Bergdoll and al., J. Bacterid., 90(5) : 1481 -1485, 1965 </p><p id="p0365" num="0365"> 7. Marr and al., Infect. Immun., 61 : 4254-4262, 1993 </p><p id="p0366" num="0366">8. Bergdoll, Lancet, 1 : 1017-1021 , 1981 </p><p id="p0367" num="0367"> 9. Blomster-Hautamaa and al., J. Biol. Chem., 261 : 15783-15786, 1986</p><p id="p0368" num="0368">10. Una and al., J. Infect. Dis., 189(12) : 2334-2336, 2004 </p><p id="p0369" num="0369"> 1 1 . Ren et al., J. Exp. Med., 180(5) : 1675-1683, 1994 </p><p id="p0370" num="0370"> 12. Jarraud and al., J. Immunol., 166(1 ) : 669-677, 2001 </p><p id="p0371" num="0371">13. Orwin and al., Infect. Immun., 69(1 ) : 360-366, 2001 </p><p id="p0372" num="0372"> 14. Letertre and al., Mol. Cell Probes, 17 : 227-235, 2003 </p><p id="p0373" num="0373">15. Omoe and al., J. Clin. Microbiol., 40 : 857-862, 2002 </p><p id="p0374" num="0374">16. Su and Wong, J. Food Prot., 59(3) : 327-330, 1996 </p><p id="p0375" num="0375">17. Munson and al., Infect. Immun., 66 : 3337-3348, 1998 </p><p id="p0376" num="0376">18. Ono and al., Infect. Immun., 76(1 1 ) : 4999-5005, 2008 </p><p id="p0377" num="0377">19. Smith and Johnson, Gene, 67(1 ) : 31 -40, 1988 </p><p id="p0378" num="0378"> 20. Habig and al., J. Biol. Chem., 249 : 7130-7139, 1974 </p><p id="p0379" num="0379"> 21 . Gampfer et al., Vaccine, 20 : 3675-3684, 2002 </p><p id="p0380" num="0380"> 22. Borkowski and al., Clin. Tech. Small Anim. Pract., 14.(1 ): 44-49, 1999 23. Soejima and al., Int. J. Food Microbiol., 93 : 185-194, 2004 </p><p id="p0381" num="0381"> 24. Macaluso et al., Analusis, 28(7 ) : 610-615, 2000 
</p></description><claims mxw-id="PCLM44852117" ref-ucid="WO-2012117342-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="0001"><!-- EPO <DP n="42"/>--><claim-text/><claim-text>CLAIMS </claim-text><claim-text>1 ) Immunological composition comprising a mixture of at least two depleted polyclonal antibodies each depleted polyclonal antibody being raised against one staphylococcal enterotoxin, and a pharmaceutically acceptable carrier. </claim-text><claim-text>2) Immunological composition according to claim 1 , comprising a mixture of at least eight depleted polyclonal antibodies each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and a pharmaceutically acceptable carrier. </claim-text><claim-text>3) Immunological composition according to claim 1 or 2, wherein each depleted polyclonal antibody is raised against one staphylococcal enterotoxin chosen from the group consisting of the staphylococcal enterotoxins A, B, C, D, E, G, H, and I. </claim-text><claim-text>4) Method for multiplex detection of staphylococcal enterotoxins, comprising: </claim-text><claim-text> a) contacting a sample with an immunological composition as defined in any of claim 1 to 3 ; </claim-text><claim-text> b) detecting potential immunological complexes formed. </claim-text><claim-text>5) Use of an immunological composition as defined in any of claim 1 to 3, as a diagnostic tool of a staphylococcal enterotoxin contamination. </claim-text><claim-text>6) Kit for the multiplex detection of staphylococcal enterotoxins, comprising an immunological composition as defined in any of claim 1 to 3, and means for the detection of immunological complexes. 7) Method for the preparation of a depleted polyclonal antibody raised against a staphylococcal enterotoxin, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin polyclonal antibody previously obtained from the immunization of a non-human animal with a staphylococcal enterotoxin ; b) purification of said anti-enterotoxin polyclonal antibody using at least two successive depletion steps against immunization-unrelated staphylococcal enterotoxins and which order is chosen to abolish cross-reactions with said immunization-unrelated staphylococcal enterotoxins from the strongest cross- reaction to the weaker cross-reaction. 
<!-- EPO <DP n="43"/>-->
 8) Method according to claim 7 for the preparation of a depleted anti- enterotoxin A polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin A polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin A ; </claim-text><claim-text> b) purification of said anti-enterotoxin A polyclonal antibody following 5 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin E, E, I, B, then D. 9) Method according to claim 7 for the preparation of a depleted anti- enterotoxin B polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin B polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin B ; </claim-text><claim-text> b) purification of said anti-enterotoxin B polyclonal antibody following 3 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin C1 , C1 , then G. </claim-text><claim-text>10) Method according to claim 7 for the preparation of a depleted anti- enterotoxin C polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin C polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin C ; </claim-text><claim-text> b) purification of said anti-enterotoxin C1 polyclonal antibody following 3 successive depletion steps against immunization-unrelated staphylococcal enterotoxin B, B, then G; </claim-text><claim-text>11 ) Method according to claim 7 for the preparation of a depleted anti- enterotoxin D polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin D polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin D ; </claim-text><claim-text> b) purification of said anti-enterotoxin D polyclonal antibody following 3 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin A, A, then E. </claim-text><claim-text>12) Method according to claim 7 for the preparation of a depleted anti- enterotoxin E polyclonal antibody, comprising : 
<!-- EPO <DP n="44"/>-->
 a) providing an anti-enterotoxin E polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin E ; </claim-text><claim-text> b) purification of said anti-enterotoxin E polyclonal antibody following 4 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin A, A, I, then C1 . </claim-text><claim-text>13) Method according to claim 7 for the preparation of a depleted anti- enterotoxin G polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin G polyclonal antibodiy previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin G ; </claim-text><claim-text> b) purification of said anti-enterotoxin A polyclonal antibody following 4 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin A, B, I, then C1 . </claim-text><claim-text>14) Method according to claim 7 for the preparation of a depleted anti- enterotoxin H polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin H polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin H ; </claim-text><claim-text> b) purification of said anti-enterotoxin A polyclonal antibody following 2 successive depletion steps against the immunization-unrelated staphylococcal enterotoxin B, then D. </claim-text><claim-text>15) Method according to claim 7 for the preparation of a depleted anti- enterotoxin I polyclonal antibody, comprising : </claim-text><claim-text> a) providing an anti-enterotoxin I polyclonal antibody previously obtained from the immunization of a non-human animal with the staphylococcal enterotoxin I ; </claim-text><claim-text> b) purification of said anti-enterotoxin I polyclonal antibody following 5 successive depletion steps against immunization-unrelated staphylococcal enterotoxin E, C1 , G, B, then A. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
